

# Chapter 2

## Stem Cell Therapy in Traumatic Brain Injury

Sicong Tu and Jian Tu

### 2.1 Introduction

Traumatic brain injury remains a leading cause of mortality and long-term disability worldwide. Traumatic brain injury results in enormous losses to individuals, families, and communities (Corrigan et al. 2010). World Health Organization has estimated that 25 % of road traffic collisions requiring admission to a hospital suffered traumatic brain injury in 2004 (Corrigan et al. 2010; [Atlas: country resources for neurological disorders home page](#); [Global burden of disease estimates](#)). World Health Organization has also introduced the new metric tool – the disability adjusted life year, which quantifies the burden of diseases, injuries and risk factors. The worldwide leading causes of traumatic brain injury include road traffic accidents that were estimated being 41.2 million disability adjusted life year in 2008, violence being responsible for 21.7 million disability adjusted life year, and self-inflicted injuries being 19.6 million disability adjusted life year, respectively. All these will leave disability associated with traumatic brain injury in survivors ([Atlas: country resources for neurological disorders home page](#); [Global burden of disease estimates](#)).

However, no effective therapy or program is available for treatment of individuals with traumatic brain injury; nonetheless, researchers had tried some therapeutic agents like levodopa/carbidopa and some neurotrophic factors in brain injury with persistent vegetative state with the aim of augmenting and slowing the progression from persistent vegetative state into some degree of consciousness.

---

S. Tu

Neuroscience Research Australia, Randwick, NSW, Australia  
e-mail: [s.tu@neura.edu.au](mailto:s.tu@neura.edu.au)

J. Tu (✉)

Prince of Wales Clinical School, University of New South Wales,  
Sydney, NSW 2031, Australia  
e-mail: [j.tu@unsw.edu.au](mailto:j.tu@unsw.edu.au)

This still needs experimentation to confirm if these dopamine precursors and other neurotrophic factors have any role in traumatic brain injury. Several other therapeutic agents like cannabinoid dexamabinol, erythropoietin, and gamma-glutamylcysteine ethyl ester have all shown to have neuroprotective effect in human at experimental stage with remarkable improvement in post-traumatic brain injury outcome (Nori et al. 2012; Ugoya and Akinyemi 2010; Biegon 2004; Lok et al. 2011; Maas 2001).

Recent advancement in knowledge about stem cells promotes the translation of stem cells to therapy in traumatic brain injury. The stem cells may play an important role in the treatment of traumatic brain injury by replacing damaged cells, and helping long-term functional recovery. The search for stem cell therapy for traumatic brain injury is promising and progressing. One obstacle in the search for an effective stem cell therapy is that the pathophysiology of traumatic brain injury is largely unknown. This is because multiple cell types like neuronal cells, glial, and endothelial cells are usually involved in traumatic brain injury. Furthermore, cerebral vasculature, especially the blood brain barrier may be affected in traumatic brain injury; this injury may be focal or diffuse axonal injury. Taming these burgeoning effects of traumatic brain injury requires neural stem cells which can differentiate into neurons and glial cells. It has been reported that progenitor cells differentiated into neurons and glial in adult brain, and an increase in astrocytic progeny forming reactive astrocytes to primarily limit cyst enlargement in posttraumatic syringomyelia (Mammis et al. 2009; Stoica et al. 2009; Tu et al. 2010, 2011).


This chapter is an optional extra to confirm whether we can achieve the translation of basic knowledge of neural stem cells into therapeutic options in persons with traumatic brain injury by enhancing and integrating these neural precursor cells unto neurogenesis and directing these cells to the specified targets or through multipotency where the transplanted stem cells can differentiate into glial cells, neurons and endothelial cells. As traumatic brain injuries are not always focal but diffuse we need to induce these transplanted stem cells differentiating into appropriate phenotype for long term structural and functional recovery. This chapter critically reviews current literatures on neural stem cell research and proposing an approach for quality clinical translation of stem cell research to therapy in traumatic brain injury. The author explains the pathophysiology of traumatic brain injury and proposes the “six point schematic approach” to achieving quality bench to bedside translation of neural stem cells to therapy for traumatic brain injury. The author also highlights the need for suitable clinical translation, coordination, and administration of research in the field of stem cell therapy for traumatic brain injury.

## 2.2 Neuropathology of Traumatic Brain Injury

Neuropathology of traumatic brain injury involves two main phases. These are the primary brain injury following the trauma, and the secondary injury which are mediated by inflammatory response to the primary brain injury.

### 2.2.1 Primary Injury After Traumatic Brain Injury


Neuropathology of the initial brain injury has been postulated to include acceleration, deceleration, and rotational forces which may or may not be as a result of the trauma. This sequence of events leads to the initiation of inertia which is both acceleration and rotational head movement. This impact on the cortical and sub-cortical brain structures causes focal or diffuse axonal injury and these inertial forces disrupt the blood brain barrier (Albert-Weissenberger et al. 2012). The primary events also involve massive ionic influx referred to as traumatic depolarization. The major inflammatory neurotransmitters released from the damaged tissue are excitatory amino acids, which may explain the neuropathology of diffuse axonal injury in traumatic brain injury. This is followed by cerebral edema with associated increase in intracranial pressure, usually forms the major immediate consequences of traumatic brain injury. Brain edema may come from astrocyte swelling and disruption of the blood brain barrier (Povlishock 1992; Greve and Zink 2009). The blood brain barrier is disrupted in acute phase of severe traumatic brain injury. The expression of high levels of glucose transporter 1 was observed in capillaries from acutely injured brain, which occurs in association with compromised blood brain barrier function. Vascular endothelial growth factor also plays a role in neuronal tissue disruption and increases the permeability of the blood brain barrier via the synthesis and release of nitric oxide. Figure 2.1 depicts the neuropathology of the primary injury after traumatic brain injury.



**Fig. 2.1** Sequential events of the primary injury in traumatic brain injury. Initial impact is usually by direct trauma to the head either open or closed head injury. This trauma causes mechanical damage to neurons, axons, glia, and blood vessels by shearing, tearing or stretching. Blood vessel ruptures cause hemorrhage. Even in unruptured blood vessels, the permeability of blood brain barrier increases resulting in edema. Hemorrhage and edema often lead to intracranial hypertension. Following hemorrhage, ischemia could occur in brain tissue. Traumatic brain injury caused cell damage induces macrophage and lymphocytes migrant to the injury site releasing inflammatory mediators that triggers a cascade of events towards necrosis and/or apoptosis. Necrosis and/or apoptosis also can be a consequence of hemorrhage and ischemia

### 2.2.2 Secondary Injury After Traumatic Brain Injury

The secondary events are a complex association of the inflammatory response initiated by the trauma leading to diffuse neuronal degeneration of neurons, glial, axonal tearing, and genetic predisposition (Fig. 2.2). Furthermore, excitatory amino acids release, oxygen radical reactions, and nitric oxide production lead to the activation of N-methyl-D-aspartate, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid,  $\alpha$ 7 nicotinic receptor ( $\alpha$ 7), and nicotinic acetylcholine receptor (Hinzman et al. 2012; Goforth et al. 2009; Kelso and Oestreich 2012) and subsequent calcium influx. All these cascades of events cause mitochondrial disruption and free radical release with eventual tissue peroxidation. One theory is that excitatory amino acid release leads to calcium influx into neurons and other brain cells which promote oxygen free radical reactions. High calcium and the presence of free-radical molecules create an unstable environment in the brain cells that lead to increased



**Fig. 2.2** Sequential events of the secondary injury in traumatic brain injury. This includes variety of processes, such as depolarization, disruption of ionic homeostasis and release of neurotransmitters, lipid degradation, and oxidative stress. These events are a result of interaction between the excitatory amino acids released with an influx of oxygen free radicals that ultimately set up N-methyl-D-aspartate, 2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid,  $\alpha$ 7 and nicotinic acetylcholine receptor to sustain the unstable environment for cell injury and degenerative changes

production and release of nitric oxide and excitatory amino acids, such as glutamate. Nitric oxide participates in oxygen radical reactions and lipid peroxidation in neighboring cells (Stoffel et al. 2001). A summary of the secondary injury after traumatic brain injury is shown in Fig. 2.2. The secondary injury plays a major role in the outcome of traumatic brain injury. Therapeutic interventions should target this phase as it is the major determinant of morbidity and mortality in traumatic brain injury (Nawashiro et al. 1994). Clinically, the application of stem cell therapy early to patients with traumatic brain injury is ethically challenging because of the difficulty in obtaining informed consent immediately following the brain injury. Genes implicated to influence the outcome of traumatic brain injury include *apoe*, *comt*, *drd2*, *ace*, and *cacna1a*. *Apoe* multifactorially affects the clinicopathological consequences of traumatic brain injury (Potapov et al. 2010). *Apoe* is associated with increased amyloid deposition, amyloid angiopathy, larger intracranial hematomas, and more severe contusional injury. *Comt* and *drd2* are genes which influence dopamine-dependent cognitive and behavioral processes, such as executive or frontal lobe functions. The *ace* gene affects traumatic brain injury outcome *via* alteration of cerebral blood flow and/or autoregulation. The *cacna1a* gene exerts an influence *via* the calcium channel pathways and its effect on delayed cerebral edema (Jordan 2007). Increased signal transducers and activator of transcription 3 signaling has been reported in a rodent model of traumatic brain injury (Oliva et al. 2012). Although several potential genes that may influence the outcomes following traumatic brain injury have been identified, future investigations are needed to validate these genetic studies, and identify new genes that might contribute to the patient outcomes after traumatic brain injury.

### 2.3 Current Pharmacotherapy for Traumatic Brain Injury

Pharmacotherapies aim at promoting neurorepair, neuroregeneration, and neuroprotection following traumatic brain injury. Clinical trials evaluating these interventions apply standardized clinical outcome measures to demonstrate efficacy. In the past, drug research and development for traumatic brain injury focused on limiting secondary brain injury after the initial traumatic event because of lacking evidence that the central nervous system could be repaired or regenerated. Growing body of evidence indicates that the adult brain can be repaired and regenerated after traumatic brain injury. Potential drug targets for post-traumatic injury brain repair include angiogenesis, axon guidance and remodeling, remyelination, neurogenesis, and synaptogenesis. Pharmacotherapies may also target brain regeneration by enhancing the capacity of pluripotent cells to differentiate into neurons, glia, and vascular endothelium (Jin et al. 2011; Valable et al. 2010; Xiong et al. 2008a, 2010a; Yatsiv et al. 2005; Zhang et al. 2009, 2010). Brain repair and regeneration processes can be activated or enhanced by pharmacotherapy over a longer therapeutic window than pharmacologic interventions designed to limit injury. Pharmacotherapies are potentially effective in the acute, subacute, post-acute, and chronic phases after

traumatic brain injury. Thus, repair and regeneration therapies have the potential advantage of being effective over a prolonged period of time following traumatic brain injury.

Currently, no effective pharmacologic agent has received approval from the U.S. Food and Drug Administration for the treatment of patients with traumatic brain injury. Table 2.1 lists candidate compounds currently undergoing clinical evaluation for traumatic brain injury treatment. Because traumatic brain injury damages the brain tissue by multiple mechanisms, combination therapy designed to simultaneously target multiple mechanisms of injury is likely required. To date, all phase II/III traumatic brain injury clinical trials have failed (Xiong et al. 2012; Watanabe et al. 2013). Stem cell therapy offers an alternative option for traumatic brain injury.

## 2.4 Stem Cell Therapy in Traumatic Brain Injury

There are at least two strategies involving stem cell therapy to repair injured brain tissue. They are transplantation of exogenous stem cells to replace damaged cells and stimulation of endogenous stem cells to proliferate to the number of cells needed and differentiate them to the phenotype of cells required for normalization of brain function.

### 2.4.1 *Transplantation of Exogenous Stem Cells in Traumatic Brain Injury*

There is great number of attempts to transplant various types of cells, such as neurons, and neural stem cells to repair damaged brain tissue. The main objectives of transplantation experiments are (1) growth facilitation: the transplant fills the lesion site and serves as a cellular bridge; (2) new neurons: the transplant can provide new neurons, which in turn provide new targets and sources of innervations and thus repair the damaged neural circuits; (3) factor secretion: the transplant can produce a variety of substances, such as neurotrophic factors, that promote the brain tissue repair process (Barami and Diaz 2000). Several characteristics of neural stem cells make them potentially suitable to repair damaged brain tissue after traumatic brain injury. Firstly, they can serve as a renewable supply of transplantable cells by clonal expansion in cell culture. Secondly, they are of central nervous system origin and the stem cells generated from the grafts have neural characteristics. Thirdly, neural stem cells can be manipulated by genetic engineering methods to produce specific proteins, such as neurotrophins, neurotransmitters and enzymes (Pincus et al. 1998).

It has been reported that autologous cultured cells harvested at time of emergency surgery from patients with traumatic brain injury, and subsequently engrafted into damaged part of the brain can be detected using magnetic resonance imaging

**Table 2.1** Pharmacotherapies currently undergoing clinical evaluation for traumatic brain injury treatment

Compound	Neuroprotective mechanism	Preclinical evidence	Clinical evidence	References
Progesterone	Enhances behavioral and functional outcomes, myelination and neurogenesis Decreases brain edema, apoptosis, pro-inflammatory cytokines Inhibits gamma-aminobutyric acid receptors Prevents neuronal cell death	Reduces IL-6, IL-1 $\beta$ , TNF- $\alpha$ , mitochondrial dysfunction, neuronal loss, axonal injury, tissue loss, lesion size, intracranial pressure, astrocytic accumulation Inhibits neuronal calcium signalling, Toll-like receptor signalling Modulates aquaporin 4 expression, NFk-B signalling, cell proliferation Enhances CD55 production, superoxide dismutase activity, levels of neurotrophin factors Protects against lipid peroxidation Improves spatial learning and memory, locomotor activity and outcomes, anxiety-like behaviors, motor and cognitive performance	Ongoing Phase III clinical trials are positive	Atif et al. (2013), Abdel Baki et al. (2010), Hammond et al. (1983), Lacroix et al. (1987), Lanthier and Patwardhan (1986), Weill-Engerer et al. (2002), Koenig et al. (1995), Liu et al. (2009), Porcu et al. (2009), Sayeed et al. (2006, 2009), Hua et al. (2011, 2012), Cutler et al. (2006, 2007), Galani et al. (2009), Grossman et al. (2004, 2011), Shahrokhi et al. (2010, 2012), Kasturi and Stein (2009), Pan et al. (2007), Guo et al. (2006), Robertson et al. (2006), Roof et al. (1992, 1994, 1996, 1997), Cekic et al. (2012), Chen et al. (2007a, 2008a, b), O'Connor et al. (2007), Yao et al. (2005), Djebaili et al. (2004, 2005), He et al. (2004), Sarkaki et al. (2013), VanLandingham et al. (2007), Jones et al. (2005), Peterson et al. (2012), Luoma et al. (2011, 2012), Garcia-Estrada et al. (1993, 1999), Petrus et al. (2005), Barha et al. (2011), Anderson et al. (2011), Wali et al. (2011), Gilmer et al. (2008), Wright et al. (2007), Xiao et al. (2008), Benvenaga et al. (2000)
Growth hormone	Normalize growth hormone deficiency/insufficiency occurred as a result of direct pituitary or indirect hypothalamic injury in 20 % TBI patients Has neuroprotective and neuroregenerative effects	Improves motor function, spatial learning and memory Enhances learning and memory retention Corrects impairments of endothelial progenitor cells Has direct autocrine and/or paracrine neuroprotective effects, anti-apoptotic effect, wound healing effects	Cognitive improvement in growth hormone deficiency/insufficiency TBI patients FDA-approved for adult patients with acquired growth hormone deficiency	Benvenaga et al. (2000), Berg et al. (2010), Kelly et al. (2000), Lieberman et al. (2001), Urban (2006), Wilkinson et al. (2012), Giordano et al. (2005), Saatman et al. (1997), Doulah et al. (2009), Svensson et al. (2006), Thum et al. (2007), Creighton et al. (2004), Ling et al. (2007), Barling et al. (2010), Sanders et al. (2008, 2010), Demling (1999, 2005), Herndon et al. (1990), Luo et al. (2000), Devesa et al. (2013), High et al. (2010), Reimunde et al. (2011), Takala et al. (1999)

(continued)

Table 2.1 (continued)

Compound	Neuroprotective mechanism	Preclinical evidence	Clinical evidence	References
Acetylcholinesterase inhibitors: Physostigmine, Donepezil, Rivastigmine, Galantamine	Increases synaptic acetylcholine by inhibiting its breakdown in the synaptic cleft	Reduces TBI-induced neuronal death, BBB disruption, vasogenic brain edema Preserves neurons hippocampal region, neurologic and motor function	FDA-approved for treating cognitive disorders, including moderate and severe TBI	Cardenas et al. (1994), McLean et al. (1987), Ballesteros et al. (2008), Blount et al. (2002), Bourgeois et al. 2002, Foster and Spiegel (2008), Fujiki et al. (2006, 2008), Hayashida et al. (2007), Kaye et al. (2003), Khateb et al. (2005), Liepert (2008), Lombardi (2008), Masanic et al. (2001), Morey et al. (2003), Sugden et al. (2006), Taverni et al. (1998), Tenovuo (2005), Trovato et al. (2006), Walker et al. (2004), Wheaton et al. (2011), Whelan et al. (2000), Whitlock (1999), Zhang et al. (2004), Chen et al. (1998a, b), Noble and Hauser (2007), Silver et al. (2006, 2009), Tenovuo et al. (2009), Weinstock et al. (2001)
Huperzine A	A selective and reversible acetylcholinesterase inhibitors extracted from a Chinese herb An NMDA antagonist Neuroprotective effects through the activation of cholinergic systems and by potentially upregulating $\beta$ -amyloid precursor protein metabolism	Modulates both amyloidogenic and non-amyloidogenic pathways Attenuates cognitive deficits Improves memory	Huperzine A is classified as an herbal remedy, has beneficial effects in cerebral blood flow, general cognitive function, global clinical status, behavior disturbance, and functional performance.	Zhang et al. (2008), Wang et al. (2002, 2012), Fan et al. (2005), Li et al. (2008), Amen et al. (2011)



Lithium	Exerts neuroprotective effects through reduction of excitotoxicity, ischemic damage, and apoptosis Attenuates several pathways involving pro-inflammatory cytokines, $\beta$ -APP-cleaving enzyme-1 expression, $\beta$ -amyloid accumulation, microglial activation, cyclooxygenase-2 activity, glycogen synthase kinase-3 $\beta$ activity, and MMP-9 expression Preserves the integrity of the BBB	Attenuates A $\beta$ load, amyloid precursor protein load, $\beta$ -APP-cleaving enzyme-1 overexpression, Tau protein phosphorylation, TBI-induced neuronal death Reduces brain edema, neuronal and hemispheric volume loss, levels of IL-1 $\beta$ Improves spatial learning and memory	The primary drug for the treatment of bipolar disorder	Shapira et al. (2007), Yu et al. (2012a, b), Zhu et al. (2010), Dash et al. (2011), Bellus et al. (1996), Glenn et al. (1989), Haas and Cope (1985), Hale and Donaldson (1982), Parmelee and O'Shanick (1988), Schiff et al. (1982)
N-acetyl cysteine	Deacetylates to cysteine in the liver Both N-acetyl cysteine and cysteine are anti-oxidants that largely scavenge cytosolic radicals Increases levels of the endogenous anti-oxidant glutathione and extracellular levels of glutamate	Anti-inflammatory activity by decreasing the activation of NF-kB, lowering IL-1 $\beta$ , TNF- $\alpha$ , and ICAM-1 levels Reduces lesion volume, levels of the putative neuroprotective enzyme heme oxidase Prevents myelin loss Restores memory	Significant increases in symptom resolution in individuals who suffer post-concussive symptoms	Abdel Baki et al. (2010), Atkuri et al. (2007), Dodd et al. (2008), Olive et al. (2012), Hicdonmez et al. (2006), Chen et al. (2008c), Yi and Hazell (2005), Hanci et al. (2010), Thomale et al. (2006), Hoffer et al. (2013)

(continued)

**Table 2.1** (continued)

Compound	Neuroprotective mechanism	Preclinical evidence	Clinical evidence	References
Cyclosporine A	Inhibits opening of the mitochondrial permeability transition pore, and protein phosphatase calcineurin Reduces reactive oxygen species	Have beneficial effects on axonal injury, contusion volume, cerebral microcirculation	Phase II clinical trial, a positive effect on 6-month Glasgow Outcome Scale score was observed in TBI patients	Abdel Baki et al. (2010), Brustovetsky and Dubinsky (2000), Sharov et al. (2007), Alessandri et al. (2002), Buki et al. (1999), Colley et al. (2010), Kilbaugh et al. (2011), Mbye et al. (2009), Okonkwo and Povlishock (1999), Okonkwo et al. (2003), Scheff and Sullivan (1999), Setkowicz and Guzic (2007), Signoretti et al. (2004), Suehiro and Povlishock (2001), Sullivan et al. (1999, 2000a, b, 2011), Turkoglu et al. (2010), Van Den Heuvel et al. (2004), Gijtenbeek et al. (1999), Wijdieks et al. (1996), Empey et al. (2006), Mazzeo et al. (2006, 2008, 2009), Hatton et al. (2008)
FK 506	Inhibits calcineurin	Have beneficial effects on axonal injury, cerebral microcirculation	Chronic neurotoxicity	Singleton et al. (2001), Campbell et al. (2012), Oda et al. (2011), Pilgaard et al. (2011), Rhodes et al. (2009), Saganová et al. (2012), Grimbirt et al. (1999)
Methylphenidate	Increases synaptic dopamine by blocking dopamine transporters and inhibiting dopamine reuptake Enhances synaptic norepinephrine levels by blocking norepinephrine reuptake	Promotes striatal dopaminergic neurotransmission Enhances spatial learning and retention and motor performance	FDA-approved for the treatment of attention deficit hyperactivity disorder Ongoing clinical trials in TBI patients	Moeller et al. (2012), Volkow et al. (1998, 2001, 2002a, b, 2012), Koda et al. (2010), Marsteller et al. (2002), Wagner et al. (2007, 2009a, b), Kline et al. (2000), Alban et al. (2004), Willmott and Ponsford (2009), Kim et al. 2006, 2012), Whyte et al. (1997, 2004), Plenger et al. (1996), Speech et al. (1993), Mahalick et al. (1998), Lee et al. (2005), Mooney and Haas (1993), Williams et al. (1998), Gualtieri and Evans (1988), Moein et al. (2006)
Atomoxetine	Inhibits norepinephrine transporters Increases extracellular norepinephrine and dopamine.	Enhances spatial learning and retention and motor performance	ibid	Koda et al. (2010), Swanson et al. (2006), Bymaster et al. (2002), Reid and Hamm (2008)


Erythropoietin	A pleiotropic cytokine involved in erythropoiesis Attenuates glutamate and nitric oxide toxicity, anti-apoptotic, anti-oxidant, and anti-inflammatory effects Stimulates neurogenesis and angiogenesis Protects mitochondria	Increases hematocrit by 60%	Ongoing Phase III clinical trials are safe and beneficial, resulting in lower hospital mortality	Jin et al. (2011), Valable et al. (2010), Xiong et al. (2008a, b, 2009, 2010a, b, 2011), Yatsiv et al. (2005), Zhang et al. (2009, 2010), Lu et al. (2005), Akdemir Ozisik et al. (2007), Bian et al. (2010), Chauhan and Gatto (2010), Chen et al. (2007b), Cherian et al. (2007), Cheria et al. (2011), Hartley et al. (2008), Liao et al. (2009), Lieutaud et al. (2008), Oztürk et al. (2008), Verdonck et al. (2007), Gonzalez et al. (2007), Ehrenreich et al. (2009), Tseng et al. (2009), Heesch et al. (2003), Miskowiak et al. (2010), Wüstenberg et al. (2011)
Glyburide	A sulfonyleurea binds sulfonylurea receptors blocking ATP-sensitive K <sup>+</sup> channels in neurons.	Reduces inflammation, hemorrhage, vasogenic edema, hippocampal injury	Ongoing Phase II clinical trial shows changes in edema and/or hemorrhage in moderate or severe TBI	Silver et al. (2009), Simard et al. (2009, 2012), Patel et al. (2010), Ortega et al. (2012), Kuntze et al. (2007)
Minocycline	Has anti-inflammatory, anti-apoptotic, and anti-oxidant activity	Inhibits microglia, T cells, neutrophils, metalloproteinases, apoptosis, reactive oxygen species Reduces lesion volume Maintains myelin content Protects grey and white matter	Confirmed as an anti-inflammatory drug	Abdel Baki et al. (2010), Kim and Suh (2009), Bye et al. (2007), Homisi et al. (2010), Sanchez Mejia et al. (2001), Kovessi et al. (2012), Casha et al. (2012), Racette (2008), Sacktor et al. (2011)
Statins: Simvastatin	Has beneficial effects in brain edema, BBB integrity, cerebral blood flow, neuroinflammation, axonal injury, cell death, trophic factor production	Against neuronal death	Ongoing Phase II clinical trial in adults with TBI	Chauhan and Gatto (2010), Abrahamson et al. (2009), Béziaud et al. (2011), Chen et al. (2008d, 2009), Indraswari et al. (2012), Li et al. (2009), Lu et al. (2004a, b, c, 2007), Wang et al. (2007), Sierra et al. (2011), Boimel et al. (2009)

(continued)

Table 2.1 (continued)

Compound	Neuroprotective mechanism	Preclinical evidence	Clinical evidence	References
Amantadine	Increases extracellular dopamine by blocking dopamine reuptake, facilitating dopamine synthesis Has postsynaptic effects on dopamine circuits by increasing dopamine receptor density antagonist of NMDA receptors		Phase III clinical trial in 184 patients in the vegetative state or minimally conscious state shows improvement in the Disability Rating Scale, representing the first and only evidence to date that pharmacologic intervention can affect recovery from TBI.	Bales et al. (2009), Gianutsos et al. (1985), Stoof et al. (1992), Dixon et al. (1999), Meythaler et al. (2002), Schneider et al. (1999), Whyte et al. (2005), Giacino et al. (2012)

Abbreviations: *IL* interleukin, *TNF* tumor necrosis factor, *NFκB* nuclear factor kappa-light-chain-enhancer of activated B cells, *TBI* traumatic brain injury, *FDA* the U.S. Food and Drug Administration, *BBB* blood brain barrier, *NMDA* N-methyl-D-aspartate, *Aβ* β-amyloid, *MMP* matrix metalloproteinase, *ICAM* intercellular adhesion molecule



**Fig. 2.3** (a) Proposed schema for effective translation of stem cells to therapy in traumatic brain injury involving concerted effort of multilevel strategies of six main stakeholders. (b) Proposed framework for the reinforcement of the multilevel strategies effective bench to bedside translation of stem cells to therapy in traumatic brain injury

(Nakamura et al. 2003). The efficacy of transplantation largely depends on a grafting method that optimizes the survival of the transplanted stem cells and minimizes the graft-induced lesion. Most transplantation studies involved intraparenchymal injection into the central nervous system, in which cells were grafted directly into or adjacent to the lesion (Chow et al. 2000; Cao et al. 2001; Jendelová et al. 2004). The optimal time for transplantation may not be immediately after injury. The levels of various inflammatory cytokines (tumor necrosis factor alpha, interleukin-1 $\alpha$ , interleukin-1 $\beta$  and interleukin-6) in the injured brain peak 6–12 h after injury and remain elevated until the 4th day. Although these inflammatory cytokines are known to have both neurotoxic and neurotrophic effects, they are believed to be neurotoxic within a week after injury, which causes the microenvironment to be unsuitable for survival of the grafted stem cells (Zhu et al. 2006). However, if too much time passes after the injury, glial scar forms a barrier surrounding the lesion site and inhibits revascularization of the graft preventing local blood circulation which is needed for graft survival. Thus, it is considered those 7–14 days after traumatic brain injury is the optimal time for stem cell transplantation (Ogawa et al. 2002; Okano et al. 2003).

#### ***2.4.2 Stimulation of Endogenous Neural Precursor Cells in Traumatic Brain Injury***

Endogenous neurogenesis has been identified in adult brain (Luskin et al. 1996; Alvarez-Buylla et al. 2000). In adult rodent brain, neural stem cells migrate from ventricular zone to the olfactory bulb and integrate into the neuronal network. This is called the rostral migratory stream. However, the potential success of stimulating endogenous neural precursor cells is hinged on delivery of various growth factors. This is the most common way to stimulate neural precursor cells. The following growth factors are needed to stimulate neural precursor cells: epidermal growth factor, fibroblast growth factor-2 (Martens et al. 2002; Kojima and Tator 2000, 2002), basic fibroblast growth factor (Rabchevsky et al. 2000), acidic fibroblast growth factor (Lee et al. 2004), brain-derived neurotrophic factor (Namiki et al. 2000; Wang et al. 2013), vascular endothelial growth factor (Sharma 2003; Chang et al. 2013), nerve growth factor, neurotrophin-3 (Namiki et al. 2000; Widenfalk et al. 2003), glial cell line-derived neurotrophic factor (Iannotti et al. 2004), insulin-like growth factor-1 (Sharma 2003), and stromal cell-derived factor-1 alpha (Imitola et al. 2004). They were administrated by intraventricular (Martens et al. 2002), intraparenchymal (Namiki et al. 2000; Sharma 2003) or intrathecal (Kojima and Tator 2000, 2002; Rabchevsky et al. 2000; Iannotti et al. 2004) injection. They were reported not only to enhance the proliferation, migration and gliogenesis of neural precursor cells (Martens et al. 2002; Kojima and Tator 2000, 2002; Imitola et al. 2004) but also to protect the spinal cord from further damage (Sharma 2003; Widenfalk et al. 2003). In addition, these growth factors facilitate the regrowth of

axons and remyelination (Lee et al. 2004; Namiki et al. 2000; Gensert and Goldman 1997). Functional recovery has been reported after growth factors were delivered into injured spinal cord (Martens et al. 2002; Kojima and Tator 2000, 2002; Lee et al. 2004). However, the mechanisms of functional recovery by stimulating endogenous neural precursor cells are not fully understood.

In addition to growth factors, other molecules are shown to stimulate endogenous neural precursor cells. Proliferation of endogenous neural precursor cells was demonstrated when the sodium channel blocker, tetrodotoxin and the glycoprotein molecule, sonic hedgehog were injected into the parenchyma (Rosenberg et al. 2005; Bambakidis et al. 2003). It has been reported that cognate chemokine receptor type 4 expressed by neural precursor cells can regulate their proliferation and direct their migration towards the injury site (Imitola et al. 2004). In addition, antibodies blocking interleukin-6 receptors were reported to not only inhibit differentiation of endogenous neural stem cells into astroglia *in vivo* and *in vitro*, but also to promote functional recovery (Okada et al. 2004; Nakamura et al. 2005). The functional recovery is resulting from blocking interleukin-6 and consequently inhibiting the formation of glial scars and promoting axonal regeneration (Okada et al. 2004; Okano et al. 2005). Notably, studies of ATP-binding cassette (ABC) transporters have emerged as a new field of investigation. ATP-binding cassette transporters, especially ATP-binding cassette sub-family A member 2, ATP-binding cassette sub-family A member 3, ATP-binding cassette sub-family B member 1, and ATP-binding cassette sub-family G member 2, play an important role in proliferation and differentiation of neural stem cells (Lin et al. 2006; Eckford and Sharom 2006; Leite et al. 2007; Li et al. 2007; Saito et al. 2007; Tamura et al. 2006).

In contrast to transplantation of exogenous neural precursor cells, stimulation of endogenous neural precursor cells to repair damaged spinal cord has three main advantages: (1) there is no ethical issue involved in human embryonic stem cells, (2) it is usually less invasive since no surgical procedure required, and (3) no immunogenicity, which avoids immunorejection that observed in the transplantation of exogenous neural precursor cells (Mohapel and Brundin 2004). Similar to the transplantation studies of adult neural precursor cells in spinal cord injury, no neurogenesis has been reported from the stimulation of endogenous neural precursor cells. It has been reported that up-regulation of the Notch signal pathways leads to poor neuronal differentiation (Yamamoto et al. 2001). The increased levels of various cytokines within the microenvironment surrounding the area of injury cause a lack of trophic support for differentiation of neural precursor cells into neuronal lineage (Okano et al. 2003; Frisén et al. 1995; Johansson et al. 1999; Widenfalk et al. 2001).

Recently, more attention has been drawn to cAMP response element binding protein/p300-phosphorylated Smad protein complex. It was found that cAMP response element binding protein/p300-phosphorylated Smad protein complex can be bound in neural stem cells, which determines the differentiation of neural stem cells. If the complex is bound with phosphorylated signal transducers and activator of transcription 3, the neural stem cells differentiate into astroglia lineage cells. On the other hand, if the complex is bound with proneural-type of the basic

helix-loop-helix factor, such as neurogenin 1 and 2, they differentiate into the neuronal lineage (Okano et al. 2005; Sun et al. 2001; Nakashima et al. 1999). Apart from that, SOX gene may also play an important role in neural differentiation (Pevny and Placzek 2005). Once neural stem cells decide to differentiate into neuronal lineage, a cascade of hundreds of genes is regulated over time to lead the immature neuron into its mature phenotype. Many of these neural genes are controlled by RE1-silencing transcription factor. RE1-silencing transcription factor acts as a repressor of neural genes in non-neural cells, while regulation of RE1-silencing transcription factor activates large networks of genes required for neural differentiation (Gage and McAllister 2005; Ballas et al. 2005; Ballas and Mandel 2005).

## **2.5 Bench to Bedside Translation of Stem Cell Therapy in Traumatic Brain Injury**

The main purpose of state-of-the-scientific studies is to translate our discoveries into daily clinical practice. The basic research laboratory takes its observations obtained at molecular or cellular levels in a cutting edge state and implements this into acceptable clinical practice to the benefit of the public. However, this is always met with a lot of challenges, such as ethics, governmental regulations, funding constraints, paucity of adequate collaboration among clinical and basic scientists, and the challenges during conducting clinical trials. From the identified gaps in the current state of the stem cell science and inherent challenges faced by the field, the author proposes six point schema for improving bench to bedside translation of stem cell therapy in Fig. 2.3a involving a rigorous network of six stakeholders: basic researchers, pharmaceutical companies, patients or general public participating in clinical trials, regulatory bodies or government agencies for providing research grant approval, collaborative research between basic and clinical scientists with the plan of developing biomarkers for potential drug targets and creating a concerted network of groups that identifies some of the medical problems relating to traumatic brain injury. Patients with moderate traumatic brain injury who suffer long-term complications are a major unmet medical need. Within our capabilities to clinically assess improvement, historically, the majority of individuals with moderate traumatic brain injury are likely to recover to their pre-injury state. Early identification of those individuals likely to experience long-term complications is essential to maximize benefit of stem cell therapy. Strategies to delineate this population from a larger population of individuals with moderate traumatic brain injury could include enrollment of patients with persistent symptoms 1–2 weeks after injury, because recovery is most rapid in the first few days. Patients who are unlikely to fully recover could be identified using prognostic biomarkers including neuroimaging, biochemical, and objective clinical measures. Prognostic biomarkers are defined by the U.S. Food and Drug Administration as indicators that inform the natural history of a disorder in the absence of a therapeutic intervention (Drug Administration 2010).



Although identifying individuals with traumatic brain injury who are most likely to respond to stem cell therapy and evaluating the biologic response to the therapy are essential for successful clinical trials, the ability to do either is lacking. Predictive biomarkers of stem cell therapeutic response are needed to address this challenge. Predictive biomarkers are baseline characteristics that identify individuals by their likelihood to respond to a stem cell therapy and may include biochemical markers including oxidative stress, inflammation, neuronal, and glial integrity, molecular imaging with positron emission tomography, or functional imaging with functional magnetic resonance imaging. By identifying patients who are most likely to respond to stem cell therapy, the appropriate population can be selected for enrollment in clinical trials. Identifying specific predictive biomarkers would decrease the sample size needed to power clinical trials, thus decreasing risk to subjects, time to complete accrual, and cost. Biomarkers are dynamic measurements that show a biologic response occurred after stem cell therapy, including neuroimaging to measure effects on neuroprotection, neurorecovery, and neuroinflammation, or biochemical biomarkers of oxidative stress, inflammation, and neuronal integrity. Clinical trials would greatly benefit from biomarkers, which allow for the measurement of the effect of the stem cell therapy on the putative mechanism of a specific phenotype of cell's action, thus providing evidence of engagement of the target tissue by the therapy. To achieve stem cell repair, regeneration and protection after traumatic brain injury, each of the six points identified is critical for advancing the field, and efforts to address the points should be conducted in parallel to ensure ultimate success in improving clinical care and outcomes for individuals with traumatic brain injury. We are still faced with the need to formulate hypothesis both at experimental and clinical epidemiologic level and implementing these into clinical practice while the translational researchers serve to collaborate and coordinate all these strategies to yield rapid results.

Indeed, communication and dissemination shown in Fig. 2.3b which is patient centredness will not only impact on the public, but will also help to tame the ethical issues in this field. Communication will involve both patients and clinicians involve in conducting randomized clinical trials. With strong feedback on outcomes, pharmacovigilance, and health promotion. Education of the populace in form of scientific advocacy is so paramount as this will impact on improved scientific collaboration, quality public control, and increased transparency among researchers and may improve funding of research work (Keramaris et al. 2008).

Research in neural stem cells is still a grey area and much knowledge needs to be gained at the bench in order to actually close the knowledge gaps in stem cell therapy. There is inadequate understanding of the secondary brain injury process after traumatic brain injury, insufficient preclinical testing in diffuse axonal injury models, species differences, and lack of understanding of the mechanism of drug-receptor interactions. It has been suggested the need to use gyrencephalic models for proper translation of stem cell therapy in traumatic brain injury (Loane and Faden 2010). Academic and biotech researchers should address how to make their stem cell therapy products more feasible for commercial-scale production (Eaker

et al. 2013). There is need for increased linkages and networking between academician, researchers, and clinician for greater reward of what is being generated.

Methodological disparities between experimental models of traumatic brain injury and clinical studies cannot be overemphasized. The intent to treat models, differences in statistical analysis as a result of different sample size, and different behaviours between human and animals. Animal research is a rapid, well-controlled, and cost-effective means to initially verify hypothesis. However, limitations exist in animal models of traumatic brain injury and their application in stem cell therapy. First, because no single animal model accurately mimics all of the features of human traumatic brain injury, individual investigators have appropriately refined experimental approaches to better fit their specific research goals. However, the resulting variability in experimental approaches among studies makes comparison of results across laboratories and models difficult, limiting the confidence that results can be translated into successful clinical trials. Advancing preclinical research in animal models requires that results are comparable across studies and can translate into human studies. This requires standardization of available animal models and introduction of new models when scientifically necessary. Second, some of the popular current models do not correspond well with the human condition. Injury severities in animals differ from humans; while they are well defined in animals, it could take any direction in human. Third, preclinical studies should use the same level of rigor required for clinical trials. Specifically, assignment of animals to treatment conditions should be randomized, assessments must be conducted by blinded examiners, the primary outcome measure must be pre-determined, and statistical assessment of secondary outcome measures should utilize appropriate corrections for multiple comparisons. Fourth, the transplantation of stem cells into animal models should mimic the timing, delivery route, and equivalent mass of cells feasible in humans. Last, the neurobehavioral outcome measures most widely used in preclinical models are not sufficiently sensitive to long-term behavioral and cognitive deficits, and more sensitive rodent behavioral tasks that discriminate injury severity beyond 12 weeks after injury are needed. The need to improve study quality score has recently being called for by stroke therapy academic industry roundtable, which was recently updated and this include the following recommendations: (1) Elimination of randomizations and assessment bias, (2) Use of a priori definitions of inclusion/exclusion criteria, (3) inclusion of appropriate power and sample size calculations, (4) full disclosure of potential conflict of interests, (5) evaluation of therapies in male and female animals across the spectrum of ages, and with comorbid conditions, such as hypertension and/or diabetes. Furthermore, some researchers has expanded on these proposed recommendations for improved clinical trials in brain injury with special focus on neuroprotective therapies in traumatic brain injury (Loane and Faden 2010; Fisher et al. 2009). Nonadherence was the single most important determinant of trial failure in the past.

Finally, the International Mission on Prognosis and Clinical Trial Design in traumatic brain injury proposed ways of overcoming the above disparities and challenges. The recommendations include a robust inclusion criteria and recommendations for general research in traumatic brain injury (Loane and Faden

2010). The six point schema is an overview recommendation with the public, patient or the society as the core and the fulcrum of all activities of research and if implemented may yield quality research outcome in neural stem cells therapy in traumatic brain injury (Ugoya and Tu 2012).

## 2.6 Conclusion

Mortality and long-term disability from traumatic brain injury is projected to rise globally. Neural stem cell therapy is a strategy that offers hope for the future in treatment of brain injury. In addition, we are now able to monitor autologous neural stem cells *in vivo*, cell migration, and clearly demonstrate that neural stem cells could selectively target injured brain or spinal cord tissue and undergo neurogenesis. Finally, the proposed six points cyclical schema should be implemented with determined effort of all stakeholders for effective bench to bedside translation of neural stem cell therapy in traumatic brain injury.

## References

- Abdel Baki SG, Schwab B, Haber M, Fenton AA, Bergold PJ (2010) Minocycline synergizes with N-acetylcysteine and improves cognition and memory following traumatic brain injury in rats. *PLoS One* 5, e12490. doi:[10.1371/journal.pone.0012490](https://doi.org/10.1371/journal.pone.0012490)
- Abrahamson EE, Ikonomic MD, Dixon CE, DeKosky ST (2009) Simvastatin therapy prevents brain trauma-induced increases in beta-amyloid peptide levels. *Ann Neurol* 66:407–414
- Akdemir Ozisik P, Oruckaptan H, Ozdemir Geyik P, Misirlioglu M, Sargon MF, Kilinc K, Ozgen T (2007) Effect of erythropoietin on brain tissue after experimental head trauma in rats. *Surg Neurol* 68:547–555
- Alban JP, Hopson MM, Ly V, Whyte J (2004) Effect of methylphenidate on vital signs and adverse effects in adults with traumatic brain injury. *Am J Phys Med Rehabil* 83:131–137
- Albert-Weissenberger C, Varrallyay C, Raslan F, Kleinschnitz C, Siren AL (2012) An experimental protocol for mimicking pathomechanisms of traumatic brain injury in mice. *Exp Transl Stroke Med* 4:1. doi:[10.1186/2040-7378-4-1](https://doi.org/10.1186/2040-7378-4-1)
- Alessandri B, Rice AC, Levasseur J, DeFord M, Hamm RJ, Bullock MR (2002) Cyclosporin A improves brain tissue oxygen consumption and learning/memory performance after lateral fluid percussion injury in rats. *J Neurotrauma* 19:829–841
- Alvarez-Buylla A, Herrera DG, Wichterle H (2000) The subventricular zone: source of neuronal precursors for brain repair. *Prog Brain Res* 127:1–11
- Amen DG, Wu JC, Taylor D, Willeumier K (2011) Reversing brain damage in former NFL players: implications for traumatic brain injury and substance abuse rehabilitation. *J Psychoactive Drugs* 43:1–5
- Anderson GD, Farin FM, Bammler TK, Beyer RP, Swan AA, Wilkerson H-W, Kantor ED, Hoane MR (2011) The effect of progesterone dose on gene expression after traumatic brain injury. *J Neurotrauma* 28:1827–1843
- Atif F, Yousuf S, Sayeed I, Ishrat T, Hua F, Stein DG (2013) Combination treatment with progesterone and vitamin D hormone is more effective than monotherapy in ischemic stroke: the role of BDNF/TrkB/Erk1/2 signaling in neuroprotection. *Neuropharmacology* 67:78–87

- Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA (2007) N-Acetylcysteine – a safe antidote for cysteine/glutathione deficiency. *Curr Opin Pharmacol* 7:355–359
- Atlas: country resources for neurological disorders home page. [http://www.who.int/mental\\_health/neurology/epidemiology/en/index.html](http://www.who.int/mental_health/neurology/epidemiology/en/index.html). Accessed 15 May 2012
- Bales JW, Wagner AK, Kline AE, Dixon CE (2009) Persistent cognitive dysfunction after traumatic brain injury: a dopamine hypothesis. *Neurosci Biobehav Rev* 33:981–1003
- Ballas N, Mandel G (2005) The many faces of REST oversee epigenetic programming of neuronal genes. *Curr Opin Neurobiol* 15:500–506
- Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G (2005) REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. *Cell* 121:645–657
- Ballesteros J, Güemes I, Ibarra N, Quemada JI (2008) The effectiveness of donepezil for cognitive rehabilitation after traumatic brain injury: a systematic review. *J Head Trauma Rehabil* 23:171–180
- Bambakidis NC, Wang RZ, Franic L, Miller RH (2003) Sonic hedgehog-induced neural precursor proliferation after adult rodent spinal cord injury. *J Neurosurg* 99 Suppl:70–75
- Barami K, Diaz FG (2000) Cellular transplantation and spinal cord injury. *Neurosurgery* 47:691–700
- Barha CK, Ishrat T, Epp JR, Galea LAM, Stein DG (2011) Progesterone treatment normalizes the levels of cell proliferation and cell death in the dentate gyrus of the hippocampus after traumatic brain injury. *Exp Neurol* 231:72–81
- Barlund A, Karlsson N, Åberg ND, Björk-Eriksson T, Blomgren K, Isgaard J (2010) The growth hormone secretagogue hexarelin increases cell proliferation in neurogenic regions of the mouse hippocampus. *Growth Horm IGF Res* 20:49–54
- Bellus SB, Stewart D, Vergo JG, Kost PP, Grace J, Barkstrom SR (1996) The use of lithium in the treatment of aggressive behaviours with two brain-injured individuals in a state psychiatric hospital. *Brain Inj* 10:849–860
- Benvenha S, Campenní A, Ruggeri RM, Trimarchi F (2000) Clinical review 113: hypopituitarism secondary to head trauma. *J Clin Endocrinol Metab* 85:1353–1361
- Berg C, Oeffner A, Schumm-Draeger P-M, Badorrek F, Brabant G, Gerbert B, Bornstein S, Zimmermann A, Weber M, Broecker-Preuss M, Mann K, Herrmann BL (2010) Prevalence of anterior pituitary dysfunction in patients following traumatic brain injury in a German multi-centre screening program. *Exp Clin Endocrinol Diabetes* 118:139–144
- Béziaud T, Ru Chen X, El Shafey N, Fréchaud M, Teng F, Palmier B, Beray-Berthar V, Soustrat M, Margail I, Plotkine M, Marchand-Leroux C, Besson VC (2011) Simvastatin in traumatic brain injury: effect on brain edema mechanisms. *Crit Care Med* 39:2300–2307
- Bian X, Yuan X, Qi C (2010) Effect of recombinant human erythropoietin on serum S100B protein and interleukin-6 levels after traumatic brain injury in the rat. *Neurol Med Chir (Tokyo)* 50:361–366
- Biegon A (2004) Cannabinoids as neuroprotective agents in traumatic brain injury. *Curr Pharm Des* 10:2177–2183
- Blount PJ, Nguyen CD, McDevitt JT (2002) Clinical use of cholinomimetic agents: a review. *J Head Trauma Rehabil* 17:314–321
- Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, Rosenmann H (2009) Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. *J Neuropathol Exp Neurol* 68:314–325
- Bourgeois JA, Bahadur N, Minjares S (2002) Donepezil for cognitive deficits following traumatic brain injury: a case report. *J Neuropsychiatry Clin Neurosci* 14:463–464
- Brustovetsky N, Dubinsky JM (2000) Limitations of cyclosporin A inhibition of the permeability transition in CNS mitochondria. *J Neurosci* 20:8229–8237
- Büki A, Okonkwo DO, Povlishock JT (1999) Postinjury cyclosporin A administration limits axonal damage and disconnection in traumatic brain injury. *J Neurotrauma* 16:511–521
- Bye N, Habgood MD, Callaway JK, Malakooti N, Potter A, Kossmann T, Morganti-Kossmann MC (2007) Transient neuroprotection by minocycline following traumatic brain injury is associated

- with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. *Exp Neurol* 204:220–233
- Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. *Neuropsychopharmacology* 27:699–711
- Campbell JN, Register D, Churn SB (2012) Traumatic brain injury causes an FK506-sensitive loss and an overgrowth of dendritic spines in rat forebrain. *J Neurotrauma* 29:201–217
- Cao QL, Zhang YP, Howard RM, Walters WM, Tsoulfas P, Whittemore SR (2001) Pluripotent stem cells engrafted into the normal or lesioned adult rat spinal cord are restricted to a glial lineage. *Exp Neurol* 167:48–58
- Cardenas DD, McLean A Jr, Farrell-Roberts L, Baker L, Brooke M, Haselkorn J (1994) Oral physostigmine and impaired memory in adults with brain injury. *Brain Inj* 8:579–587
- Casha S, Zygun D, McGowan MD, Bains I, Yong VW, Hurlbert RJ (2012) Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury. *Brain* 135:1224–1236
- Cekic M, Johnson SJ, Bhatt VH, Stein DG (2012) Progesterone treatment alters neurotrophin/proneurotrophin balance and receptor expression in rats with traumatic brain injury. *Restor Neurol Neurosci* 30:115–126
- Chang CP, Chio CC, Cheong CU, Chao CM, Cheng BC, Lin MT (2013) Hypoxic preconditioning enhances the therapeutic potential of the secretome from cultured human mesenchymal stem cells in experimental traumatic brain injury. *Clin Sci* 124:165–176
- Chauhan NB, Gatto R (2010) Synergistic benefits of erythropoietin and simvastatin after traumatic brain injury. *Brain Res* 1360:177–192
- Chen Y, Shohami E, Constantini S, Weinstock M (1998a) Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse. *J Neurotrauma* 15:231–237
- Chen Y, Shohami E, Bass R, Weinstock M (1998b) Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat. *Brain Res* 784:18–24
- Chen G, Shi J, Ding Y, Yin H, Hang C (2007a) Progesterone prevents traumatic brain injury-induced intestinal nuclear factor kappa B activation and proinflammatory cytokines expression in male rats. *Mediators Inflamm* 2007:93431
- Chen G, Shi JX, Hang CH, Xie W, Liu J, Liu X (2007b) Inhibitory effect on cerebral inflammatory agents that accompany traumatic brain injury in a rat model: a potential neuroprotective mechanism of recombinant human erythropoietin (rhEPO). *Neurosci Lett* 425:177–182
- Chen G, Shi J-X, Qi M, Wang H-X, Hang C-H (2008a) Effects of progesterone on intestinal inflammatory response, mucosa structure alterations, and apoptosis following traumatic brain injury in male rats. *J Surg Res* 147:92–98
- Chen G, Shi J, Jin W, Wang L, Xie W, Sun J, Hang C (2008b) Progesterone administration modulates TLRs/NF-kappaB signaling pathway in rat brain after cortical contusion. *Ann Clin Lab Sci* 38:65–74
- Chen G, Shi J, Hu Z, Hang C (2008c) Inhibitory effect on cerebral inflammatory response following traumatic brain injury in rats: a potential neuroprotective mechanism of N-acetylcysteine. *Mediators Inflamm* 2008:716458
- Chen XR, Besson VC, Beziaud T, Plotkine M, Marchand-Leroux C (2008d) Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury. *J Pharmacol Exp Ther* 326:966–974
- Chen G, Zhang S, Shi J, Ai J, Qi M, Hang C (2009) Simvastatin reduces secondary brain injury caused by cortical contusion in rats: possible involvement of TLR4/NF-kappaB pathway. *Exp Neurol* 216:398–406
- Cherian L, Goodman JC, Robertson C (2007) Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. *J Pharmacol Exp Ther* 322:789–794

- Cherian L, Goodman JC, Robertson C (2011) Improved cerebrovascular function and reduced histological damage with darbepoietin alfa administration after cortical impact injury in rats. *J Pharmacol Exp Ther* 337:451–456
- Chow SY, Moul J, Tobias CA, Himes BT, Liu Y, Obrocka M, Hodge L, Tessler A, Fischer I (2000) Characterization and intraspinal grafting of EGF/bFGF-dependent neurospheres derived from embryonic rat spinal cord. *Brain Res* 874:87–106
- Colley BS, Phillips LL, Reeves TM (2010) The effects of cyclosporin-A on axonal conduction deficits following traumatic brain injury in adult rats. *Exp Neurol* 224:241–251
- Corrigan JD, Selassie AW, Orman JA (2010) The epidemiology of traumatic brain injury. *J Head Trauma Rehabil* 25:72–80
- Creyghton WM, van Dam PS, Koppeschaar HPF (2004) The role of the somatotrophic system in cognition and other cerebral functions. *Semin Vasc Med* 4:167–172
- Cutler SM, VanLandingham JW, Murphy AZ, Stein DG (2006) Slow-release and injected progesterone treatments enhance acute recovery after traumatic brain injury. *Pharmacol Biochem Behav* 84:420–428
- Cutler SM, Cekic M, Miller DM, Wali B, VanLandingham JW, Stein DG (2007) Progesterone improves acute recovery after traumatic brain injury in the aged rat. *J Neurotrauma* 24:1475–1486
- Dash PK, Johnson D, Clark J, Orsi SA, Zhang M, Zhao J, Grill RJ, Moore AN, Pati S (2011) Involvement of the glycogen synthase kinase-3 signaling pathway in TBI pathology and neurocognitive outcome. *PLoS One* 6, e24648
- Demling R (1999) Growth hormone therapy in critically ill patients. *N Engl J Med* 341:837–839
- Demling RH (2005) The role of anabolic hormones for wound healing in catabolic states. *J Burns Wounds* 4, e2
- Devesa J, Reimunde P, Devesa P, Barberá M, Arce V (2013) Growth hormone (GH) and brain trauma. *Horm Behav* 63:331–344
- Dixon CE, Kraus MF, Kline AE, Ma X, Yan HQ, Griffith RG, Wolfson BM, Marion DW (1999) Amantadine improves water maze performance without affecting motor behavior following traumatic brain injury in rats. *Restor Neurol Neurosci* 14:285–294
- Djebaili M, Hoffman SW, Stein DG (2004) Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. *Neuroscience* 123:349–359
- Djebaili M, Guo Q, Pettus EH, Hoffman SW, Stein DG (2005) The neurosteroids progesterone and allopregnanolone reduce cell death, gliosis, and functional deficits after traumatic brain injury in rats. *J Neurotrauma* 22:106–118
- Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (2008) N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. *Expert Opin Biol Ther* 8:1955–1962
- Doulah AH, Rohani AH, Khaksari Haddad M, Motamedi F, Farbood Y, Badavi M, Malek M, Sarkaki A (2009) The effect of peripheral administration of growth hormone on AD-like cognitive deficiency in NBM-lesioned rats. *Neurosci Lett* 466:47–51
- Food and Drug Administration (2010) Guidance for industry: qualification process for drug development tools
- Eaker S, Armant M, Brandwein H, Burger S, Campbell A, Carpenito C (2013) Concise review: guidance in developing commercializable autologous/patient-specific cell therapy manufacturing. *Stem Cells Trans Med*. doi:[10.5966/sctm.2013-0050](https://doi.org/10.5966/sctm.2013-0050) [Epub ahead of print]
- Eckford PD, Sharom FJ (2006) P-glycoprotein (ABCB1) interacts directly with lipid-based anti-cancer drugs and platelet-activating factors. *Biochem Cell Biol* 84:1022–1033
- Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, Schellinger PD, Bohn M, Becker H, Wegrzyn M, Jähnig P, Herrmann M, Knauth M, Bähr M, Heide W, Wagner A, Schwab S, Reichmann H, Schwendemann G, Dengler R, Kastrup A, Bartels C (2009) Recombinant human erythropoietin in the treatment of acute ischemic stroke. *Stroke* 40:e647–e656
- Empey PE, McNamara PJ, Young B, Rosbalt MB, Hatton J (2006) Cyclosporin A disposition following acute traumatic brain injury. *J Neurotrauma* 23:109–116



- Fan Y, Hu J, Li J, Yang Z, Xin X, Wang J, Ding J, Geng M (2005) Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms. *Neurosci Lett* 374:222–226
- Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, Lo EH, STAIR Group (2009) Update of the stroke therapy academic industry roundtable preclinical recommendations. *Stroke* 40:2244–2250
- Foster M, Spiegel DR (2008) Use of donepezil in the treatment of cognitive impairments of moderate traumatic brain injury. *J Neuropsychiatry Clin Neurosci* 20:106
- Frisén J, Johansson CB, Török C, Risling M, Lendahl U (1995) Rapid, widespread, and longlasting induction of nestin contributes to the generation of glial scar tissue after CNS injury. *J Cell Biol* 131:453–464
- Fujiki M, Hikawa T, Abe T, Ishii K, Kobayashi H (2006) Reduced short latency afferent inhibition in diffuse axonal injury patients with memory impairment. *Neurosci Lett* 405:226–230
- Fujiki M, Kubo T, Kamida T, Sugita K, Hikawa T, Abe T, Ishii K, Kobayashi H (2008) Neuroprotective and anti-amnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury. *J Clin Neurosci* 15:791–796
- Gage FH, McAllister AK (2005) Neuronal and glial cell biology. *Curr Opin Neurobiol* 15:497–499
- Galani R, Hoffman SW, Stein DG (2001) Effects of the duration of progesterone treatment on the resolution of cerebral edema induced by cortical contusions in rats. *Restor Neurol Neurosci* 18:161–166
- García-Estrada J, Del Río JA, Luquín S, Soriano E, García-Segura LM (1993) Gonadal hormones down-regulate reactive gliosis and astrocyte proliferation after a penetrating brain injury. *Brain Res* 628:271–278
- García-Estrada J, Luquín S, Fernández AM, García-Segura LM (1999) Dehydroepiandrosterone, pregnenolone and sex steroids down-regulate reactive astroglia in the male rat brain after a penetrating brain injury. *Int J Dev Neurosci* 17:145–151
- Gensert JM, Goldman JE (1997) Endogenous progenitors remyelinate demyelinated axons in the adult CNS. *Neuron* 19:197–203
- Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz DI, Cho S, Yablon SA, Luther M, Hammond FM, Nordenbo A, Novak P, Mercer W, Maurer-Karattup P, Sherer M (2012) Placebo-controlled trial of amantadine for severe traumatic brain injury. *N Engl J Med* 366:819–826
- Gianutsos G, Chute S, Dunn JP (1985) Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine. *Eur J Pharmacol* 110:357–361
- Gijtenbeek JM, van den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: a review. *J Neurol* 246:339–346
- Gilmer LK, Roberts KN, Scheff SW (2008) Efficacy of progesterone following a moderate unilateral cortical contusion injury. *J Neurotrauma* 25:593–602
- Giordano G, Aimaretti G, Ghigo E (2005) Variations of pituitary function over time after brain injuries: the lesson from a prospective study. *Pituitary* 8:227–231
- Glenn MB, Wroblewski B, Parziale J, Levine L, Whyte J, Rosenthal M (1989) Lithium carbonate for aggressive behavior or affective instability in ten brain-injured patients. *Am J Phys Med Rehabil* 68:221–226
- Global burden of disease estimates. <http://www.who.int/healthinfo/bodestimates/en/index.html>. Accessed 22 May 2012
- Goforth PB, Ellis EF, Satin LS (2009) Enhancement of AMPA-mediated current after traumatic injury in cortical neurons. *J Neurosci* 19:7367–7374
- Gonzalez FF, McQuillen P, Mu D, Chang Y, Wendland M, Vexler Z, Ferriero DM (2007) Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. *Dev Neurosci* 29:321–330
- Greve MW, Zink BJ (2009) Pathophysiology of traumatic brain injury. *Mount Sinai J Med* 76:97–104

- Grimbert P, Azema C, Pastural M, Dhamane D, Remy P, Salomon L, Schortgen F, Baron C, Lang P (1999) Tacrolimus (FK506)-induced severe and late encephalopathy in a renal transplant recipient. *Nephrol Dial Transplant* 14:2489–2491
- Grossman KJ, Goss CW, Stein DG (2004) Effects of progesterone on the inflammatory response to brain injury in the rat. *Brain Res* 1008:29–39
- Grossman KJ, Goss CW, Stein DG (2011) Sickness behaviors following medial frontal cortical contusions in male rats. *Behav Brain Res* 217:202–208
- Gualtieri CT, Evans RW (1988) Stimulant treatment for the neurobehavioural sequelae of traumatic brain injury. *Brain Inj* 2:273–290
- Guo Q, Sayeed I, Baronne LM, Hoffman SW, Guennoun R, Stein DG (2006) Progesterone administration modulates AQP4 expression and edema after traumatic brain injury in male rats. *Exp Neurol* 198:469–478
- Haas JF, Cope DN (1985) Neuropharmacologic management of behavior sequelae in head injury: a case report. *Arch Phys Med Rehabil* 66:472–474
- Hale MS, Donaldson JO (1982) Lithium carbonate in the treatment of organic brain syndrome. *J Nerv Ment Dis* 170:362–365
- Hammond GL, Hirvonen J, Vihko R (1983) Progesterone, androstenedione, testosterone, 5 alpha-dihydrotestosterone and androsterone concentrations in specific regions of the human brain. *J Steroid Biochem* 18:185–189
- Hanci V, Kerimoğlu A, Koca K, Başkesen A, Kiliç K, Taştekin D (2010) The biochemical effectiveness of N-acetylcysteine in experimental spinal cord injury in rats. *Ulus Travma Acil Cerrahi Derg* 16:15–21
- Hartley CE, Varma M, Fischer JP, Riccardi R, Strauss JA, Shah S, Zhang S, Yang Z-J (2008) Neuroprotective effects of erythropoietin on acute metabolic and pathological changes in experimentally induced neurotrauma. *J Neurosurg* 109:708–714
- Hatton J, Rosbalt B, Empey P, Kryscio R, Young B (2008) Dosing and safety of cyclosporine in patients with severe brain injury. *J Neurosurg* 109:699–707
- Hayashida K, Parker R, Eisenach JC (2007) Oral gabapentin activates spinal cholinergic circuits to reduce hypersensitivity after peripheral nerve injury and interacts synergistically with oral donepezil. *Anesthesiology* 106:1213–1219
- He J, Evans C-O, Hoffman SW, Oyesiku NM, Stein DG (2004) Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. *Exp Neurol* 189:404–412
- Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. *Blood* 102:1340–1346
- Herndon DN, Barrow RE, Kunkel KR, Broemeling L, Rutan RL (1990) Effects of recombinant human growth hormone on donor-site healing in severely burned children. *Ann Surg* 212:424–429
- Hicdonmez T, Kanter M, Tiryaki M, Parsak T, Cobanoglu S (2006) Neuroprotective effects of N-acetylcysteine on experimental closed head trauma in rats. *Neurochem Res* 31:473–481
- High WM Jr, Briones-Galang M, Clark JA, Gilkison C, Mossberg KA, Zgaljardic DJ, Masel BE, Urban RJ (2010) Effect of growth hormone replacement therapy on cognition after traumatic brain injury. *J Neurotrauma* 27:1565–1575
- Hinzman JM, Thomas TC, Quintero JE, Gerhardt GA, Lifshitz J (2012) Disruptions in the regulation of extracellular glutamate by neurons and glia in the rat striatum two days after diffuse brain injury. *J Neurotrauma* 29:1197–1208
- Hoffer ME, Balaban C, Slade MD, Tsao JW, Hoffer B (2013) Amelioration of acute sequelae of blast induced mild traumatic brain injury by N-acetyl cysteine: a double-blind, placebo controlled study. *PLoS One* 8, e54163
- Homsi S, Piaggio T, Croci N, Noble F, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M (2010) Blockade of acute microglial activation by minocycline promotes neuroprotection and reduces locomotor hyperactivity after closed head injury in mice: a twelve-week follow-up study. *J Neurotrauma* 27:911–921



- Hua F, Wang J, Ishrat T, Wei W, Atif F, Sayeed I, Stein DG (2011) Genomic profile of Toll-like receptor pathways in traumatically brain-injured mice: effect of exogenous progesterone. *J Neuroinflammation* 8:42
- Hua F, Reiss JI, Tang H, Wang J, Fowler X, Sayeed I, Stein DG (2012) Progesterone and low-dose vitamin D hormone treatment enhances sparing of memory following traumatic brain injury. *Horm Behav* 61:642–651
- Iannotti C, Zhang YP, Shields CB, Han Y, Burke DA, Xu XM (2004) A neuroprotective role of glial cell line-derived neurotrophic factor following moderate spinal cord contusion injury. *Exp Neurol* 189:317–332
- Imitola J, Raddassi K, Park KI, Mueller FJ, Nieto M, Teng YD, Frenkel D, Li J, Sidman RL, Walsh CA, Snyder EY, Khoury SJ (2004) Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1 $\alpha$ /CXC chemokine receptor 4 pathway. *Proc Natl Acad Sci U S A* 101:18117–18122
- Indraswari F, Wang H, Lei B, James ML, Kernagis D, Warner DS, Dawson HN, Laskowitz DT (2012) Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. *J Neurotrauma* 29:1388–1400
- Jendelová P, Herynek V, Urdzíkóvá L, Glogarová K, Kroupová J, Andersson B, Bryia V, Burian M, Hájek M, Syková E (2004) Magnetic resonance tracking of transplanted bone marrow and embryonic stem cells labeled by iron oxide nanoparticles in rat brain and spinal cord. *J Neurosci Res* 76:232–243
- Jin W, Kong J, Lu T, Wang H, Ni H, Wu J, Dai Y, Jiang J, Liang W (2011) Erythropoietin prevents secondary brain injury induced by cortical lesion in mice: possible involvement of Nrf2 signaling pathway. *Ann Clin Lab Sci* 41:25–32
- Johansson CB, Momma S, Clarke DL, Risling M, Lendahl U, Frisén J (1999) Identification of a neural stem cell in the adult mammalian central nervous system. *Cell* 96:25–34
- Jones NC, Constantin D, Prior MJW, Morris PG, Marsden CA, Murphy S (2005) The neuroprotective effect of progesterone after traumatic brain injury in male mice is independent of both the inflammatory response and growth factor expression. *Eur J Neurosci* 21:1547–1554
- Jordan BD (2007) Genetic influences on outcome following traumatic brain injury. *Neurochem Res* 32:905–915
- Kasturi BS, Stein DG (2009) Progesterone decreases cortical and sub-cortical edema in young and aged ovariectomized rats with brain injury. *Restor Neurol Neurosci* 27:265–275
- Kaye NS, Townsend JB 3rd, Ivins R (2003) An open-label trial of donepezil (aricept) in the treatment of persons with mild traumatic brain injury. *J Neuropsychiatry Clin Neurosci* 15:383–384
- Kelly DF, Gonzalo IT, Cohan P, Berman N, Swerdloff R, Wang C (2000) Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report. *J Neurosurg* 93:743–752
- Kelso ML, Oestreich JH (2012) Traumatic brain injury: central and peripheral role of  $\alpha 7$  nicotinic acetylcholine receptors. *Curr Drug Targets* 13:631–636
- Keramaris NC, Kanakaris NK, Tzioupi C, Kontakis G, Giannoudis PV (2008) Translational research: From benchside to bedside. *Injury* 39:643–650
- Khateb A, Ammann J, Annoni J-M, Diserens K (2005) Cognition-enhancing effects of donepezil in traumatic brain injury. *Eur Neurol* 54:39–45
- Kilbaugh TJ, Bhandare S, Lorom DH, Saraswati M, Robertson CL, Margulies SS (2011) Cyclosporin A preserves mitochondrial function after traumatic brain injury in the immature rat and piglet. *J Neurotrauma* 28:763–774
- Kim H-S, Suh Y-H (2009) Minocycline and neurodegenerative diseases. *Behav Brain Res* 196:168–179
- Kim Y-H, Ko M-H, Na S-Y, Park S-H, Kim K-W (2006) Effects of single-dose methylphenidate on cognitive performance in patients with traumatic brain injury: a double-blind placebo-controlled study. *Clin Rehabil* 20:24–30
- Kim J, Whyte J, Patel S, Europa E, Wang J, Coslett HB, Detre JA (2012) Methylphenidate modulates sustained attention and cortical activation in survivors of traumatic brain injury: a perfusion fMRI study. *Psychopharmacology (Berl)* 222:47–57

- Kline AE, Yan HQ, Bao J, Marion DW, Dixon CE (2000) Chronic methylphenidate treatment enhances water maze performance following traumatic brain injury in rats. *Neurosci Lett* 280:163–166
- Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T (2010) Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. *J Neurochem* 114:259–270
- Koenig HL, Schumacher M, Ferzaz B, Thi AN, Ressouches A, Guennoun R, Jung-Testas I, Robel P, Akwa Y, Baulieu EE (1995) Progesterone synthesis and myelin formation by Schwann cells. *Science* 268:1500–1503
- Kojima A, Tator CH (2000) Epidermal growth factor and fibroblast growth factor 2 cause proliferation of ependymal precursor cells in the adult rat spinal cord in vivo. *J Neuropathol Exp Neurol* 59:687–697
- Kojima A, Tator CH (2002) Intrathecal administration of epidermal growth factor and fibroblast growth factor 2 promotes ependymal proliferation and functional recovery after spinal cord injury in adult rats. *J Neurotrauma* 19:223–238
- Kovesdi E, Kammaksh A, Wingo D, Ahmed F, Grunberg NE, Long JB, Kasper CE, Agoston DV (2012) Acute minocycline treatment mitigates the symptoms of mild blast-induced traumatic brain injury. *Front Neurol* 3:111
- Kunte H, Schmidt S, Eliasziw M, del Zoppo GJ, Simard JM, Masuhr F, Weih M, Dirnagl U (2007) Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. *Stroke* 38:2526–2530
- Lacroix C, Fiet J, Benais JP, Gueux B, Bonete R, Villette JM, Gourmel B, Dreux C (1987) Simultaneous radioimmunoassay of progesterone, androst-4-enedione, pregnenolone, dehydroepiandrosterone and 17-hydroxyprogesterone in specific regions of human brain. *J Steroid Biochem* 28:317–325
- Lanthier A, Patwardhan VV (1986) Sex steroids and 5-en-3 beta-hydroxysteroids in specific regions of the human brain and cranial nerves. *J Steroid Biochem* 25:445–449
- Lee YS, Lin CY, Robertson RT, Hsiao I, Lin VW (2004) Motor recovery and anatomical evidence of axonal regrowth in spinal cord-repaired adult rats. *J Neuropathol Exp Neurol* 63:233–245
- Lee H, Kim S-W, Kim J-M, Shin I-S, Yang S-J, Yoon J-S (2005) Comparing effects of methylphenidate, sertraline and placebo on neuropsychiatric sequelae in patients with traumatic brain injury. *Hum Psychopharmacol* 20:97–104
- Leite DFP, Echevarria-Lima J, Calixto JB, Rumjanek VM (2007) Multidrug resistance related protein (ABCC1) and its role on nitrite production by the murine macrophage cell line RAW 264.7. *Biochem Pharmacol* 73:665–674
- Li G, Shi P, Wang Y (2007) Evolutionary dynamics of the ABCA chromosome 17q24 cluster genes in vertebrates. *Genomics* 89:385–391
- Li J, Wu HM, Zhou RL, Liu GJ, Dong BR (2008) Huperzine A for Alzheimer's disease. *Cochrane Database Syst Rev* CD005592
- Li B, Mahmood A, Lu D, Wu H, Xiong Y, Qu C, Chopp M (2009) Simvastatin attenuates microglial cells and astrocyte activation and decreases interleukin-1beta level after traumatic brain injury. *Neurosurgery* 65:179–185
- Liao ZB, Jiang GY, Tang ZH, Zhi XG, Sun XC, Tang WY, Wu MJ (2009) Erythropoietin can promote survival of cerebral cells by downregulating Bax gene after traumatic brain injury in rats. *Neurol India* 57:722–728
- Lieberman SA, Oberoi AL, Gilkison CR, Masel BE, Urban RJ (2001) Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. *J Clin Endocrinol Metab* 86:2752–2756
- Liepert J (2008) Pharmacotherapy in restorative neurology. *Curr Opin Neurol* 21:639–643
- Lieutaud T, Andrews PJD, Rhodes JKJ, Williamson R (2008) Characterization of the pharmacokinetics of human recombinant erythropoietin in blood and brain when administered immediately after lateral fluid percussion brain injury and its pharmacodynamic effects on IL-1beta and MIP-2 in rats. *J Neurotrauma* 25:1179–1185

- Lin T, Islam O, Heese K (2006) ABC transporters, neural stem cells and neurogenesis-a different perspective. *Cell Res* 16:857–871
- Ling FA, Hui DZ, Ji SM (2007) Protective effect of recombinant human somatotropin on amyloid beta-peptide induced learning and memory deficits in mice. *Growth Horm IGF Res* 17:336–341
- Liu L, Wang J, Zhao L, Nilsen J, McClure K, Wong K, Brinton RD (2009) Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. *Endocrinology* 150:3186–3196
- Loane DJ, Faden AI (2010) Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. *Trends Pharmacol Sci* 31:596–604
- Lok J, Leung W, Zhao S, Pallast S, van Leyen K, Guo S, Wang X, Yalcin A, Lo EH (2011) Gamma-glutamylcysteine ethyl ester protects cerebral endothelial cells during injury and decreases blood–brain barrier permeability after experimental brain trauma. *J Neurochem* 118:248–255
- Lombardi F (2008) Pharmacological treatment of neurobehavioural sequelae of traumatic brain injury. *Eur J Anaesthesiol Suppl* 42:131–136
- Lu D, Goussev A, Chen J, Pannu P, Li Y, Mahmood A, Chopp M (2004a) Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. *J Neurotrauma* 21:21–32
- Lu D, Mahmood A, Goussev A, Schallert T, Qu C, Zhang ZG, Li Y, Lu M, Chopp M (2004b) Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury. *J Neurosurg* 101:813–821
- Lu D, Mahmood A, Qu C, Goussev A, Lu M, Chopp M (2004c) Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact. *J Neurosurg* 101:822–825
- Lu D, Mahmood A, Qu C, Goussev A, Schallert T, Chopp M (2005) Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. *J Neurotrauma* 22:1011–1017
- Lu D, Qu C, Goussev A, Jiang H, Lu C, Schallert T, Mahmood A, Chen J, Li Y, Chopp M (2007) Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. *J Neurotrauma* 24:1132–1146
- Luo X, Cen Y, Yu R, Zhao J (2000) Effectiveness of recombinant human growth hormone treatment for severe burn injury. *Hua Xi Yi Ke Da Xue Xue Bao* 31:399–401
- Luoma JJ, Kelley BG, Mermelstein PG (2011) Progesterone inhibition of voltage-gated calcium channels is a potential neuroprotective mechanism against excitotoxicity. *Steroids* 76:845–855
- Luoma JJ, Stern CM, Mermelstein PG (2012) Progesterone inhibition of neuronal calcium signaling underlies aspects of progesterone-mediated neuroprotection. *J Steroid Biochem Mol Biol* 131:30–36
- Luskin MB, Zigova T, Soteres BJ, Stewart RR (1996) Neuronal progenitor cells derived from the anterior subventricular zone of the neonatal rat forebrain continue to proliferate in vitro and express a neuronal phenotype. *Mol Cell Neurosci* 8:351–366
- Maas AIR (2001) Neuroprotective agents in traumatic brain injury. *Expert Opin Investig Drugs* 10:753–767
- Mahalick DM, Carmel PW, Greenberg JP, Molofsky W, Brown JA, Heary RF, Marks D, Zampella E, Hodosh R, von der Schmidt E 3rd (1998) Psychopharmacologic treatment of acquired attention disorders in children with brain injury. *Pediatr Neurosurg* 29:121–126
- Mammis A, McIntosh TK, Maniker AH (2009) Erythropoietin as a neuroprotective agent in traumatic brain injury. *Surg Neurol* 71:527–531
- Marsteller DA, Gerasimov MR, Schiffer WK, Geiger JM, Barnett CR, Schaich Borg J, Scott S, Ceccarelli J, Volkow ND, Molina PE, Alexoff DL, Dewey SL (2002) Acute handling stress modulates methylphenidate-induced catecholamine overflow in the medial prefrontal cortex. *Neuropsychopharmacology* 27:163–170

- Martens DJ, Seaberg RM, van der Kooy D (2002) In vivo infusions of exogenous growth factors into the fourth ventricle of the adult mouse brain increase the proliferation of neural progenitors around the fourth ventricle and the central canal of the spinal cord. *Eur J Neurosci* 16:1045–1057
- Masanic CA, Bayley MT, VanReekum R, Simard M (2001) Open-label study of donepezil in traumatic brain injury. *Arch Phys Med Rehabil* 82:896–901
- Mazzeo AT, Kunene NK, Gilman CB, Hamm RJ, Hafez N, Bullock MR (2006) Severe human traumatic brain injury, but not cyclosporin a treatment, depresses activated T lymphocytes early after injury. *J Neurotrauma* 23:962–975
- Mazzeo AT, Alves OL, Gilman CB, Hayes RL, Tolias C, Niki Kunene K, Ross Bullock M (2008) Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study. *Acta Neurochir (Wien)* 150:1019–1031
- Mazzeo AT, Brophy GM, Gilman CB, Alves OL, Robles JR, Hayes RL, Povlishock JT, Bullock MR (2009) Safety and tolerability of cyclosporin A in severe traumatic brain injury patients: results from a prospective randomized trial. *J Neurotrauma* 26:2195–2206
- Mbye LHAN, Singh IN, Carrico KM, Saatman KE, Hall ED (2009) Comparative neuroprotective effects of cyclosporin A and NIM811, a nonimmunosuppressive cyclosporin A analog, following traumatic brain injury. *J Cereb Blood Flow Metab* 29:87–97
- McLean A Jr, Stanton KM, Cardenas DD, Bergerud DB (1987) Memory training combined with the use of oral physostigmine. *Brain Inj* 1:145–159
- Meythaler JM, Brunner RC, Johnson A, Novack TA (2002) Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. *J Head Trauma Rehabil* 17:300–313
- Miskowiak KW, Vinberg M, Harmer CJ, Ehrenreich H, Knudsen GM, Macoveanu J, Hansen AR, Paulson OB, Siebner HR, Kessing LV (2010) Effects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder. *Trials* 11:97
- Moein H, Khalili HA, Keramatian K (2006) Effect of methylphenidate on ICU and hospital length of stay in patients with severe and moderate traumatic brain injury. *Clin Neurol Neurosurg* 108:539–542
- Moeller SJ, Honorio J, Tomasi D, Parvaz MA, Woicik PA, Volkow ND, Goldstein RZ (2012) Methylphenidate enhances executive function and optimizes prefrontal function in both health and cocaine addiction. *Cereb Cortex*. doi:10.1093/cercor/bhs345
- Mohapel P, Brundin P (2004) Harnessing endogenous stem cells to treat neurodegenerative disorders of the basal ganglia. *Parkinsonism Relat Disord* 10:259–264
- Mooney GF, Haas LJ (1993) Effect of methylphenidate on brain injury-related anger. *Arch Phys Med Rehabil* 74:153–160
- Morey CE, Cilo M, Berry J, Cusick C (2003) The effect of Aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study. *Brain Inj* 17:809–815
- Nakamura M, Houghtling RA, MacArthur L, Bayer BM, Bregman BS (2003) Differences in cytokine gene expression profile between acute and secondary injury in adult rat spinal cord. *Exp Neurol* 184:313–325
- Nakamura M, Okada S, Toyama Y, Okano H (2005) Role of IL-6 in spinal cord injury in a mouse model. *Clin Rev Allergy Immunol* 28:197–203
- Nakashima K, Yanagisawa M, Arakawa H, Kimura N, Hisatsune T, Kawabata M, Miyazono K, Taga T (1999) Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. *Science* 284:479–482
- Namiki J, Kojima A, Tator CH (2000) Effect of brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 on functional recovery and regeneration after spinal cord injury in adult rats. *J Neurotrauma* 17:1219–1231
- Nawashiro H, Shima K, Chigasaki H (1994) Blood–brain barrier, cerebral blood flow, and cerebral plasma volume immediately after head injury in the rat. *Acta Neurochir* 60(Suppl):440–442
- Noble JM, Hauser WA (2007) Effects of rivastigmine on cognitive function in patients with traumatic brain injury. *Neurology* 68:1749
- Nori S, Tsuji O, Okada Y, Toyama Y, Okano H, Nakamura M (2012) Therapeutic potential of induced pluripotent stem cells for spinal cord injury. *Brain Nerve* 64:17–27

- O'Connor CA, Cernak I, Johnson F, Vink R (2007) Effects of progesterone on neurologic and morphologic outcome following diffuse traumatic brain injury in rats. *Exp Neurol* 205:145–153
- Oda Y, Gao G, Wei EP, Povlishock JT (2011) Combinational therapy using hypothermia and the immunophilin ligand FK506 to target altered pial arteriolar reactivity, axonal damage, and blood–brain barrier dysfunction after traumatic brain injury in rat. *J Cereb Blood Flow Metab* 31:1143–1154
- Ogawa Y, Sawamoto K, Miyata T, Miyao S, Watanabe M, Nakamura M, Bregman BS, Koike M, Uchiyama Y, Toyama Y, Okano H (2002) Transplantation of in vitro-expanded fetal neural progenitor cells results in neurogenesis and functional recovery after spinal cord contusion injury in adult rats. *J Neurosci Res* 69:925–933
- Okada S, Nakamura M, Mikami Y, Shimazaki T, Mihara M, Ohsugi Y, Iwamoto Y, Yoshizaki K, Kishimoto T, Toyama Y, Okano H (2004) Blockade of interleukin-6 receptor suppresses reactive astrogliosis and ameliorates functional recovery in experimental spinal cord injury. *J Neurosci Res* 76:265–276
- Okano H, Ogawa Y, Nakamura M, Kaneko S, Iwanami A, Toyama Y (2003) Transplantation of neural stem cells into the spinal cord after injury. *Semin Cell Dev Biol* 14:191–198
- Okano H, Okada S, Nakamura M, Toyama Y (2005) Neural stem cells and regeneration of injured spinal cord. *Kidney Int* 68:1927–1931
- Okonkwo DO, Povlishock JT (1999) An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury. *J Cereb Blood Flow Metab* 19:443–451
- Okonkwo DO, Melon DE, Pellicane AJ, Mutlu LK, Rubin DG, Stone JR, Helm GA (2003) Dose–response of cyclosporin A in attenuating traumatic axonal injury in rat. *Neuroreport* 14:463–466
- Oliva AA, Kang Y, Sanchez-Molano J, Furones C, Atkins CM (2012) STAT3 signaling after traumatic brain injury. *J Neurochem* 120:710–720
- Olive MF, Cleva RM, Kalivas PW, Malcolm RJ (2012) Glutamatergic medications for the treatment of drug and behavioral addictions. *Pharmacol Biochem Behav* 100:801–810
- Ortega FJ, Gimeno-Bayon J, Espinosa-Parrilla JF, Carrasco JL, Batlle M, Pugliese M, Mahy N, Rodríguez MJ (2012) ATP-dependent potassium channel blockade strengthens microglial neuroprotection after hypoxia-ischemia in rats. *Exp Neurol* 235:282–296
- Oztürk E, Demirbilek S, Köroğlu A, But A, Begeç ZO, Gülec M, Akyol O, Ersoy MO (2008) Propofol and erythropoietin antioxidant properties in rat brain injured tissue. *Prog Neuropsychopharmacol Biol Psychiatry* 32:81–86
- Pan D-S, Liu W-G, Yang X-F, Cao F (2007) Inhibitory effect of progesterone on inflammatory factors after experimental traumatic brain injury. *Biomed Environ Sci* 20:432–438
- Parmelee DX, O'Shanick GJ (1988) Carbamazepine-lithium toxicity in brain-damaged adolescents. *Brain Inj* 2:305–308
- Patel AD, Gerzanich V, Geng Z, Simard JM (2010) Glibenclamide reduces hippocampal injury and preserves rapid spatial learning in a model of traumatic brain injury. *J Neuropathol Exp Neurol* 69:1177–1190
- Peterson TC, Anderson GD, Kantor ED, Hoane MR (2012) A comparison of the effects of nicotine and progesterone on functional recovery of cognitive behavior following cortical contusion injury in the rat. *J Neurotrauma* 29:2823–2830
- Pettus EH, Wright DW, Stein DG, Hoffman SW (2005) Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury. *Brain Res* 1049:112–119
- Pevny L, Placzek M (2005) SOX genes and neural progenitor identity. *Curr Opin Neurobiol* 15:7–13
- Piilgaard H, Witgen BM, Rasmussen P, Lauritzen M (2011) Cyclosporine A, FK506, and NIM811 ameliorate prolonged CBF reduction and impaired neurovascular coupling after cortical spreading depression. *J Cereb Blood Flow Metab* 31:1588–1598
- Pincus DW, Goodman RR, Fraser RAR, Nedergaard M, Goldman SA (1998) Neural stem and progenitor cells: a strategy for gene therapy and brain repair. *Neurosurgery* 42:858–868

- Plenger PM, Dixon CE, Castillo RM, Frankowski RF, Yablon SA, Levin HS (1996) Subacute methylphenidate treatment for moderate to moderately severe traumatic brain injury: a preliminary double-blind placebo-controlled study. *Arch Phys Med Rehabil* 77:536–540
- Porcu P, O'Buckley TK, Alward SE, Marx CE, Shampine LJ, Girdler SS, Morrow AL (2009) Simultaneous quantification of GABAergic 3 $\alpha$ , 5 $\alpha$ /3 $\alpha$ , 5 $\beta$  neuroactive steroids in human and rat serum. *Steroids* 74:463–473
- Potapov AA, Iusupova MM, Tendieva VD, Nikitin AG, Nosikov VV (2010) Clinical and prognostic significance of genetic markers of ApoE gene in traumatic brain injury. *Zh Vopr Neurokhir Im N N Burdenko* 3:54–62
- Povlishock JT (1992) Traumatically induced axonal injury: pathogenesis and pathobiological implications. *Brain Pathol* 1:1–12
- Rabchevsky AG, Fugaccia I, Turner AF, Blades DA, Mattson MP, Scheff SW (2000) Basic fibroblast growth factor (bFGF) enhances functional recovery following severe spinal cord injury to the rat. *Exp Neurol* 164:280–291
- Racette B (2008) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. *Clin Neuropharmacol* 31:141–150
- Reid WM, Hamm RJ (2008) Post-injury atomoxetine treatment improves cognition following experimental traumatic brain injury. *J Neurotrauma* 25:248–256
- Reimunde P, Quintana A, Castañón B, Casteleiro N, Vilarnovo Z, Otero A, Devesa A, Otero-Cepeda XL, Devesa J (2011) Effects of growth hormone (GH) replacement and cognitive rehabilitation in patients with cognitive disorders after traumatic brain injury. *Brain Inj* 25:65–73
- Rhodes JKJ, Sharkey J, Andrews PJD (2009) The temporal expression, cellular localization, and inhibition of the chemokines MIP-2 and MCP-1 after traumatic brain injury in the rat. *J Neurotrauma* 26:507–525
- Robertson CL, Puskar A, Hoffman GE, Murphy AZ, Saraswati M, Fiskum G (2006) Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats. *Exp Neurol* 197:235–243
- Roof RL, Duvdevani R, Stein DG (1992) Progesterone treatment attenuates brain edema following contusion injury in male and female rats. *Restor Neurol Neurosci* 4:425–427
- Roof RL, Duvdevani R, Braswell L, Stein DG (1994) Progesterone facilitates cognitive recovery and reduces secondary neuronal loss caused by cortical contusion injury in male rats. *Exp Neurol* 129:64–69
- Roof RL, Duvdevani R, Heyburn JW, Stein DG (1996) Progesterone rapidly decreases brain edema: treatment delayed up to 24 hours is still effective. *Exp Neurol* 138:246–251
- Roof RL, Hoffman SW, Stein DG (1997) Progesterone protects against lipid peroxidation following traumatic brain injury in rats. *Mol Chem Neuropathol* 31:1–11
- Rosenberg LJ, Zai LJ, Wrathall JR (2005) Chronic alterations in the cellular composition of spinal cord white matter following contusion injury. *Glia* 49:107–120
- Saatman KE, Contreras PC, Smith DH, Raghupathi R, McDermott KL, Fernandez SC, Sanderson KL, Voddi M, McIntosh TK (1997) Insulin-like growth factor-1 (IGF-1) improves both neurological motor and cognitive outcome following experimental brain injury. *Exp Neurol* 147:418–427
- Sacktor N, Miyahara S, Deng L, Evans S, Schifitto G, Cohen BA, Paul R, Robertson K, Jarocki B, Scarsi K, Coombs RW, Zink MC, Nath A, Smith E, Ellis RJ, Singer E, Weihe J, McCarthy S, Hosey L, Clifford DB (2011) Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. *Neurology* 77:1135–1142
- Saganová K, Gálík J, Blaško J, Korimová A, Račková E, Vanický I (2012) Immunosuppressant FK506: focusing on neuroprotective effects following brain and spinal cord injury. *Life Sci* 91:77–82
- Saito T, Yamada K, Wang Y, Tanaka Y, Ohtomo K, Ishikawa K, Inagaki N (2007) Expression of ABCA2 protein in both non-myelin-forming and myelin-forming Schwann cells in the rodent peripheral nerve. *Neurosci Lett* 414:35–40
- Sanchez Mejia RO, Ona VO, Li M, Friedlander RM (2001) Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. *Neurosurgery* 48:1393–1399



- Sanders EJ, Parker E, Harvey S (2008) Growth hormone-mediated survival of embryonic retinal ganglion cells: signaling mechanisms. *Gen Comp Endocrinol* 156:613–621
- Sanders EJ, Lin W-Y, Parker E, Harvey S (2010) Growth hormone expression and neuroprotective activity in a quail neural retina cell line. *Gen Comp Endocrinol* 165:111–119
- Sarkaki AR, Khaksari M, Soltani Z, Shahrokhi N, Mahmoodi M (2013) Time- and dose-dependent neuroprotective effects of sex steroid hormones on inflammatory cytokines after a traumatic brain injury. *J Neurotrauma* 30:47–54
- Sayeed I, Guo Q, Hoffman SW, Stein DG (2006) Allopregnanolone, a progesterone metabolite, is more effective than progesterone in reducing cortical infarct volume after transient middle cerebral artery occlusion. *Ann Emerg Med* 47:381–389
- Sayeed I, Parvez S, Wali B, Siemen D, Stein DG (2009) Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. *Brain Res* 1263:165–173
- Scheff SW, Sullivan PG (1999) Cyclosporin A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents. *J Neurotrauma* 16:783–792
- Schiff HB, Sabin TD, Geller A, Alexander L, Mark V (1982) Lithium in aggressive behavior. *Am J Psychiatry* 139:1346–1348
- Schneider WN, Drew-Cates J, Wong TM, Dombovy ML (1999) Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study. *Brain Inj* 13:863–872
- Setkowicz Z, Guzik R (2007) Injections of vehicle, but not cyclosporin A or tacrolimus (FK506), afford neuroprotection following injury in the developing rat brain. *Acta Neurobiol Exp (Wars)* 67:399–409
- Shahrokhi N, Khaksari M, Soltani Z, Mahmoodi M, Nakhaee N (2010) Effect of sex steroid hormones on brain edema, intracranial pressure, and neurologic outcomes after traumatic brain injury. *Can J Physiol Pharmacol* 88:414–421
- Shahrokhi N, Haddad MK, Joukar S, Shabani M, Keshavarzi Z, Shahozehi B (2012) Neuroprotective antioxidant effect of sex steroid hormones in traumatic brain injury. *Pak J Pharm Sci* 25:219–225
- Shapira M, Licht A, Milman A, Pick CG, Shohami E, Eldar-Finkelman H (2007) Role of glycogen synthase kinase-3 $\beta$  in early depressive behavior induced by mild traumatic brain injury. *Mol Cell Neurosci* 34:571–577
- Sharma HS (2003) Neurotrophic factors attenuate microvascular permeability disturbances and axonal injury following trauma to the rat spinal cord. *Acta Neurochir* 86(Suppl):383–388
- Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN (2007) Cyclosporine A attenuates mitochondrial permeability transition and improves mitochondrial respiratory function in cardiomyocytes isolated from dogs with heart failure. *J Mol Cell Cardiol* 42:150–158
- Sierra S, Ramos MC, Molina P, Esteo C, Vázquez JA, Burgos JS (2011) Statins as neuroprotectants: a comparative in vitro study of lipophilicity, blood–brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. *J Alzheimers Dis* 23:307–318
- Signoretti S, Marmarou A, Tavazzi B, Dunbar J, Amorini AM, Lazzarino G, Vagnozzi R (2004) The protective effect of cyclosporin A upon N-acetylaspartate and mitochondrial dysfunction following experimental diffuse traumatic brain injury. *J Neurotrauma* 21:1154–1167
- Silver J, Koumaras B, Chen M, Mirski D, Potkin SG, Reyes P, Warden D, Harvey PD, Arciniegas D, Katz DI, Gunay I (2006) Effects of rivastigmine on cognitive function in patients with traumatic brain injury. *Neurology* 67:748–755
- Silver J, Koumaras B, Meng X, Potkin SG, Reyes PF, Harvey PD, Katz DI, Gunay I, Arciniegas DB (2009) Long-term effects of rivastigmine capsules in patients with traumatic brain injury. *Brain Inj* 23:123–132
- Simard JM, Kilbourne M, Tsybalyuk O, Tosun C, Caridi J, Ivanova S, Keledjian K, Bochicchio G, Gerzanich V (2009) Key role of sulfonylurea receptor 1 in progressive secondary hemorrhage after brain contusion. *J Neurotrauma* 26:2257–2267
- Simard JM, Woo SK, Schwartzbauer GT, Gerzanich V (2012) Sulfonylurea receptor 1 in central nervous system injury: a focused review. *J Cereb Blood Flow Metab* 32:1699–1717

- Singleton RH, Stone JR, Okonkwo DO, Pellicane AJ, Povlishock JT (2001) The immunophilin ligand FK506 attenuates axonal injury in an impact-acceleration model of traumatic brain injury. *J Neurotrauma* 18:607–614
- Speech TJ, Rao SM, Osmon DC, Sperry LT (1993) A double-blind controlled study of methylphenidate treatment in closed head injury. *Brain Inj* 7:333–338
- Stoffel M, Rinecker M, Plesnila N, Eriskat J, Baethmann A (2001) Role of nitric oxide in the secondary expansion of a cortical brain lesion from cold injury. *J Neurotrauma* 18:425–434
- Stoica B, Byrnes K, Faden AI (2009) Multifunctional drug treatment in neurotrauma. *Neurotherapeutics* 6:14–27
- Stoof JC, Booij J, Drukarch B (1992) Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? *Clin Neurol Neurosurg* 94 Suppl:S4–S6
- Suehiro E, Povlishock JT (2001) Exacerbation of traumatically induced axonal injury by rapid posthypothermic rewarming and attenuation of axonal change by cyclosporin A. *J Neurosurg* 94:493–498
- Sugden SG, Kile SJ, Farrimond DD, Hilty DM, Bourgeois JA (2006) Pharmacological intervention for cognitive deficits and aggression in frontal lobe injury. *NeuroRehabilitation* 21:3–7
- Sullivan PG, Thompson MB, Scheff SW (1999) Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury. *Exp Neurol* 160:226–234
- Sullivan PG, Thompson M, Scheff SW (2000a) Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury. *Exp Neurol* 161:631–637
- Sullivan PG, Rabchevsky AG, Hicks RR, Gibson TR, Fletcher-Turner A, Scheff SW (2000b) Dose–response curve and optimal dosing regimen of cyclosporin A after traumatic brain injury in rats. *Neuroscience* 101:289–295
- Sullivan PG, Sebastian AH, Hall ED (2011) Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury. *J Neurotrauma* 28:311–318
- Sun Y, Nadal-Vicens M, Misono S, Lin MZ, Zubiaga A, Hua X, Fan G, Greenberg ME (2001) Neurogenin promotes neurogenesis and inhibits glial differentiation by independent mechanisms. *Cell* 104:365–376
- Svensson J, Diez M, Engel J, Wass C, Tivesten A, Jansson J-O, Isaksson O, Archer T, Hökfelt T, Ohlsson C (2006) Endocrine, liver-derived IGF-I is of importance for spatial learning and memory in old mice. *J Endocrinol* 189:617–627
- Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP (2006) Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. *Neuropharmacology* 50:755–760
- Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G, Hinds CJ (1999) Increased mortality associated with growth hormone treatment in critically ill adults. *N Engl J Med* 341:785–792
- Tamura A, Wakabayashi K, Onishi Y, Nakagawa H, Tsuji M, Matsuda Y, Ishikawa T (2006) Genetic polymorphisms of human ABC transporter ABCG2: development of the standard method for functional validation of SNPs by using the Flp recombinase system. *J Exp Ther Oncol* 6:1–11
- Taverni JP, Seliger G, Lichtman SW (1998) Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation. *Brain Inj* 12:77–80
- Tenovuo O (2005) Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients. *Prog Neuropsychopharmacol Biol Psychiatry* 29:61–67
- Tenovuo O, Alin J, Helenius H (2009) A randomized controlled trial of rivastigmine for chronic sequels of traumatic brain injury-what it showed and taught? *Brain Inj* 23:548–558
- Thomale U-W, Griebenow M, Kroppenstedt S-N, Unterberg AW, Stover JF (2006) The effect of N-acetylcysteine on posttraumatic changes after controlled cortical impact in rats. *Intensive Care Med* 32:149–155
- Thum T, Hoeber S, Froese S, Klink I, Stichtenoth DO, Galuppo P, Jakob M, Tsikas D, Anker SD, Poole-Wilson PA, Borlak J, Ertl G, Bauersachs J (2007) Age-dependent impairment of endo-



- thelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. *Circ Res* 100:434–443
- Trovato M, Slomine B, Pidcock F, Christensen J (2006) The efficacy of donepezil hydrochloride on memory functioning in three adolescents with severe traumatic brain injury. *Brain Inj* 20:339–343
- Tseng M-Y, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ (2009) Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. *Clinical article. J Neurosurg* 111:171–180
- Tu J, Liao J, Stoodley AM, Cunningham AM (2010) Differentiation of endogenous progenitors in an animal model of post-traumatic syringomyelia. *Spine* 35:1116–1121
- Tu J, Liao J, Stoodley AM, Cunningham A (2011) Reaction of endogenous progenitor cells in a rat model of posttraumatic syringomyelia. *J Neurosurg Spine* 14:573–582
- Turkoglu OF, Eroglu H, Gurcan O, Bodur E, Sargon MF, Oner L, Beskonakli E (2010) Local administration of chitosan microspheres after traumatic brain injury in rats: a new challenge for cyclosporine – a delivery. *Br J Neurosurg* 24:578–583
- Ugoya SO, Akinyemi RO (2010) The place of l-dopa/carbidopa in persistent vegetative state. *Clin Neuropharmacol* 33:79–84
- Ugoya SO, Tu J (2012) Bench to bedside of neural stem cell in traumatic brain injury. *Stem Cells Int* 141624:8 p. doi:[10.1155/2012/141624](https://doi.org/10.1155/2012/141624)
- Urban RJ (2006) Hypopituitarism after acute brain injury. *Growth Horm IGF Res* 16 Suppl A:S25–S29
- Valable S, Francony G, Bouzat P, Fevre MC, Mahious N, Bouet V, Farion R, Barbier E, Lahrech H, Remy C, Petit E, Segebarth C, Bermaudin M, Payen JF (2010) The impact of erythropoietin on short-term changes in phosphorylation of brain protein kinases in a rat model of traumatic brain injury. *J Cereb Blood Flow Metab* 30:361–369
- Van Den Heuvel C, Donkin JJ, Finnie JW, Blumbergs PC, Kuchel T, Koszyca B, Manavis J, Jones NR, Reilly PL, Vink R (2004) Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporin-A administration. *J Neurotrauma* 21:1562–1572
- VanLandingham JW, Cekic M, Cutler S, Hoffman SW, Stein DG (2007) Neurosteroids reduce inflammation after TBI through CD55 induction. *Neurosci Lett* 425:94–98
- Verdonck O, Lahrech H, Francony G, Carle O, Farion R, Van de Looij Y, Remy C, Segebarth C, Payen J-F (2007) Erythropoietin protects from post-traumatic edema in the rat brain. *J Cereb Blood Flow Metab* 27:1369–1376
- Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. *Am J Psychiatry* 155:1325–1331
- Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. *J Neurosci* 21:RC121
- Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (2002a) Mechanism of action of methylphenidate: insights from PET imaging studies. *J Atten Disord* 6(Suppl 1):S31–S43
- Volkow ND, Wang G-J, Fowler JS, Logan J, Franceschi D, Maynard L, Ding Y-S, Gatley SJ, Gifford A, Zhu W, Swanson JM (2002b) Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. *Synapse* 43:181–187
- Volkow ND, Wang G-J, Tomasi D, Kollins SH, Wigal TL, Newcorn JH, Telang FW, Fowler JS, Logan J, Wong CT, Swanson JM (2012) Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. *J Neurosci* 32:841–849
- Wagner AK, Kline AE, Ren D, Willard LA, Wenger MK, Zafonte RD, Dixon CE (2007) Gender associations with chronic methylphenidate treatment and behavioral performance following experimental traumatic brain injury. *Behav Brain Res* 181:200–209

- Wagner AK, Drewencki LL, Chen X, Santos FR, Khan AS, Harun R, Torres GE, Michael AC, Dixon CE (2009a) Chronic methylphenidate treatment enhances striatal dopamine neurotransmission after experimental traumatic brain injury. *J Neurochem* 108:986–997
- Wagner AK, Sokoloski JE, Chen X, Harun R, Clossin DP, Khan AS, Andes-Koback M, Michael AC, Dixon CE (2009b) Controlled cortical impact injury influences methylphenidate-induced changes in striatal dopamine neurotransmission. *J Neurochem* 110:801–810
- Wali B, Sayeed I, Stein DG (2011) Improved behavioral outcomes after progesterone administration in aged male rats with traumatic brain injury. *Restor Neurol Neurosci* 29:61–71
- Walker W, Seel R, Gibellato M, Lew H, Cornis-Pop M, Jena T, Silver T (2004) The effects of Donepezil on traumatic brain injury acute rehabilitation outcomes. *Brain Inj* 18:739–750
- Wang LS, Zhou J, Shao XM, Tang XC (2002) Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. *Brain Res* 949:162–170
- Wang H, Lynch JR, Song P, Yang H-J, Yates RB, Mace B, Warner DS, Guyton JR, Laskowitz DT (2007) Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. *Exp Neurol* 206:59–69
- Wang Y, Tang XC, Zhang HY (2012) Huperzine A alleviates synaptic deficits and modulates amyloidogenic and nonamyloidogenic pathways in APPswe/PS1dE9 transgenic mice. *J Neurosci Res* 90:508–517
- Wang Z, Yao W, Deng Q, Zhang X, Zhang J (2013) Protective effects of BDNF overexpression bone marrow stromal cell transplantation in rat models of traumatic brain injury. *J Mol Neurosci* 49:409–416
- Watanabe J, Shetty AK, Hattiangady B, Kim DK, Foraker JE (2013) Administration of TSG-6 improves memory after traumatic brain injury. *Neurobiol Dis* 59:86–99
- Weill-Engerer S, David J-P, Szadovitch V, Liere P, Eychenne B, Pianos A, Schumacher M, Delacourte A, Baulieu E-E, Akwa Y (2002) Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. *J Clin Endocrinol Metab* 87:5138–5143
- Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Youdim MB, Shoham S (2001) Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. *Ann N Y Acad Sci* 939:148–161
- Wheaton P, Mathias JL, Vink R (2011) Impact of pharmacological treatments on cognitive and behavioral outcome in the postacute stages of adult traumatic brain injury: a meta-analysis. *J Clin Psychopharmacol* 31:745–757
- Whelan FJ, Walker MS, Schultz SK (2000) Donepezil in the treatment of cognitive dysfunction associated with traumatic brain injury. *Ann Clin Psychiatry* 12:131–135
- Whitlock JA Jr (1999) Brain injury, cognitive impairment, and donepezil. *J Head Trauma Rehabil* 14:424–427
- Whyte J, Hart T, Schuster K, Fleming M, Polansky M, Coslett HB (1997) Effects of methylphenidate on attentional function after traumatic brain injury. A randomized, placebo-controlled trial. *Am J Phys Med Rehabil* 76:440–450
- Whyte J, Hart T, Vaccaro M, Grieb-Neff P, Risser A, Polansky M, Coslett HB (2004) Effects of methylphenidate on attention deficits after traumatic brain injury: a multidimensional, randomized, controlled trial. *Am J Phys Med Rehabil* 83:401–420
- Whyte J, Katz D, Long D, DiPasquale MC, Polansky M, Kalmar K, Giacino J, Childs N, Mercer W, Novak P, Maurer P, Eifert B (2005) Predictors of outcome in prolonged posttraumatic disorders of consciousness and assessment of medication effects: A multicenter study. *Arch Phys Med Rehabil* 86:453–462
- Widenfalk J, Lundströmer K, Jubran M, Brené S, Olson L (2001) Neurotrophic factors and receptors in the immature and adult spinal cord after mechanical injury or kainic acid. *J Neurosci* 21:3457–3475
- Widenfalk J, Lipson A, Jubran M, Hofstetter C, Ebendal T, Cao Y, Olson L (2003) Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury. *Neuroscience* 120:951–960

- Wijdicks EF, Plevak DJ, Wiesner RH, Steers JL (1996) Causes and outcome of seizures in liver transplant recipients. *Neurology* 47:1523–1525
- Wilkinson CW, Pagulayan KF, Petrie EC, Mayer CL, Colasurdo EA, Shofer JB, Hart KL, Hoff D, Tarabochia MA, Peskind ER (2012) High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury. *Front Neurol* 3:11
- Williams SE, Ris MD, Ayyangar R, Schefft BK, Berch D (1998) Recovery in pediatric brain injury: is psychostimulant medication beneficial? *J Head Trauma Rehabil* 13:73–81
- Willmott C, Ponsford J (2009) Efficacy of methylphenidate in the rehabilitation of attention following traumatic brain injury: a randomised, crossover, double blind, placebo controlled inpatient trial. *J Neurol Neurosurg Psychiatr* 80:552–557
- Wright DW, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC, Salomone JP, Dent LL, Harris OA, Ander DS, Lowery DW, Patel MM, Denson DD, Gordon AB, Wald MM, Gupta S, Hoffman SW, Stein DG (2007) ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. *Ann Emerg Med* 49:391–402
- Wüstenberg T, Begemann M, Bartels C, Gefeller O, Stawicki S, Hinze-Selch D, Mohr A, Falkai P, Aldenhoff JB, Knauth M, Nave K-A, Ehrenreich H (2011) Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. *Mol Psychiatry* 16:26–36
- Xiao G, Wei J, Yan W, Wang W, Lu Z (2008) Improved outcomes from the administration of progesterone for patients with acute severe traumatic brain injury: a randomized controlled trial. *Crit Care* 12:R61
- Xiong Y, Mahmood A, Lu D, Qu C, Kazmi H, Goussev A, Zhang ZG, Noguchi CT, Schallert T, Chopp M (2008a) Histological and functional outcomes after traumatic brain injury in mice null for the erythropoietin receptor in the central nervous system. *Brain Res* 1230:247–257
- Xiong Y, Lu D, Qu C, Goussev A, Schallert T, Mahmood A, Chopp M (2008b) Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. *J Neurosurg* 109:510–521
- Xiong Y, Chopp M, Lee C-P (2009) Erythropoietin improves brain mitochondrial function in rats after traumatic brain injury. *Neurol Res* 31:496–502
- Xiong Y, Mahmood A, Meng Y, Zhang Y, Qu C, Schallert T, Chopp M (2010a) Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose. *J Neurosurg* 113:598–608
- Xiong Y, Mahmood A, Qu C, Kazmi H, Zhang ZG, Noguchi CT, Schallert T, Chopp M (2010b) Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor. *J Neurotrauma* 27:205–215
- Xiong Y, Mahmood A, Zhang Y, Meng Y, Zhang ZG, Qu C, Sager TN, Chopp M (2011) Effects of posttraumatic carbamylated erythropoietin therapy on reducing lesion volume and hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome in rats following traumatic brain injury. *J Neurosurg* 114:549–559
- Xiong Y, Mahmood A, Meng Y, Zhang Y, Zhang ZG, Morris DC, Chopp M (2012) Neuroprotective and neurorestorative effects of thymosin  $\beta_4$  treatment following experimental traumatic brain injury. *Ann N Y Acad Sci* 1270:51–58
- Yamamoto SI, Nagao M, Sugimori M, Kosako H, Nakatomi H, Yamamoto N, Takebayashi H, Nabeshima Y, Kitamura T, Weinmaster G, Nakamura K, Nakafuku M (2001) Transcription factor expression and notch-dependent regulation of neural progenitors in the adult rat spinal cord. *J Neurosci* 21:9814–9823
- Yao X-L, Liu J, Lee E, Ling GSF, McCabe JT (2005) Progesterone differentially regulates pro- and anti-apoptotic gene expression in cerebral cortex following traumatic brain injury in rats. *J Neurotrauma* 22:656–668
- Yatsiv I, Grigoriadis N, Simeonidou C, Stahel PF, Schmidt OI, Alexandrovitch AG, Tsenter J, Shohami E (2005) Erythropoietin is neuroprotective, improves functional recovery, and reduces

- neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. *FASEB J* 19:1701–1703
- Yi J-H, Hazell AS (2005) N-acetylcysteine attenuates early induction of heme oxygenase-1 following traumatic brain injury. *Brain Res* 1033:13–19
- Yu F, Zhang Y, Chuang D-M (2012a) Lithium reduces BACE1 overexpression, beta amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. *J Neurotrauma* 29:2342–2351
- Yu F, Wang Z, Tchanchou F, Chiu C-T, Zhang Y, Chuang D-M (2012b) Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. *J Neurotrauma* 29:362–374
- Zhang L, Plotkin RC, Wang G, Sandel ME, Lee S (2004) Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. *Arch Phys Med Rehabil* 85:1050–1055
- Zhang HY, Yan H, Tang XC (2008) Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. *Cell Mol Neurobiol* 28:173–183
- Zhang Y, Xiong Y, Mahmood A, Meng Y, Qu C, Schallert T, Chopp M (2009) Therapeutic effects of erythropoietin on histological and functional outcomes following traumatic brain injury in rats are independent of hematocrit. *Brain Res* 1294:153–164
- Zhang Y, Xiong Y, Mahmood A, Meng Y, Liu Z, Qu C, Chopp M (2010) Sprouting of corticospinal tract axons from the contralateral hemisphere into the denervated side of the spinal cord is associated with functional recovery in adult rat after traumatic brain injury and erythropoietin treatment. *Brain Res* 1353:249–257
- Zhu J, Zhou L, Wu FX (2006) Tracking neural stem cells in patients with brain trauma. *N Engl J Med* 355:2376–2378
- Zhu Z-F, Wang Q-G, Han B-J, William CP (2010) Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice. *Brain Res Bull* 83:272–277

Neurological Regeneration

Pham, P.V. (Ed.)

2017, IX, 258 p. 30 illus., 26 illus. in color., Hardcover

ISBN: 978-3-319-33719-7